

MASTERARBEIT / MASTER'S THESIS

Titel der Masterarbeit / Title of the Master's Thesis
"C–H Activation in Natural Product Synthesis"

verfasst von / submitted by Christian Knittl-Frank, BSc

angestrebter akademischer Grad / in partial fulfilment of the requirements for the degree of Master of Science (MSc)

Wien, 2017 / Vienna 2017

Studienkennzahl It. Studienblatt / degree programme code as it appears on the student record sheet:

Studienrichtung It. Studienblatt / degree programme as it appears on the student record sheet:

Betreut von / Supervisor:

A 066 862

Masterstudium Chemie

Univ.-Prof. Dr. Nuno Maulide



Preamble

Acknowledgement

I want to thank Univ.-Prof. Dr. Nuno Maulide for giving me the opportunity to work in his group and furthermore for the assignment of this natural product synthesis. Moreover, I want to thank him for his trust in me, making me the administrator of the group's ELN+CIS. Last but not least, I would like to express my appreciation for letting me be part of his experimental show team.

Special thanks are given to Martin Berger, MSc for supervising my practical work, for his support and his advises.

Sincere thanks are given to all members of the working-group, especially the personnel of lab 1136 (Dr. Pauline Adler and Rik Oost, MSc) for a very nice working atmosphere. It was a pleasure to work with them. Thanks to Martina Drescher for the exceptional organisation of the labs and equipment. Particular thanks also to Dr. Tobias Stopka, Dr. Christopher Teskey, and Dr. Alexandre Pinto for proofreading of this thesis.

Thanks to the NMR-Team, the MS-Team and Dipl.-Ing. (FH) Alexander Roller for measurements of my compounds.

Thanks go to our Dean, o. Univ.-Prof. Dr. Dr. Bernhard K. Keppler, for letting me work as experimenter in the General Chemistry Lecture. Thanks to Ass.-Prof. Dr. Peter Unfried for the offer to support him in the exhibition "Die Schönheit der Elemente". Thanks to ao. Univ.-Prof. i.R. Mag. Dr. Helmut H. Weinke for letting me help in his courses.

Moreover, thanks go to my family and my partner Mariam Hohagen, BSc whom without it would not have been possible to spend numerous hours in tha hood (a.k.a. fume hood), and our daughter Nura for accompanying me on my ways.

List of Abbreviations

ACN acetonitrile PCC pyridinium chlorochromate

d doublet **q** quartet

DCM dichloromethane **quant** quantitative

DMF dimethyl formamide **quint** quintet

DMSO dimethyl sulfoxide s singlet

ESI electrospray ionization t triplet

GBL γ-butyrolactone TCCA trichloroisocyanuric acid

THF tetrahydrofuran

HR high resolution mass spectroscopy

TLC thin layer chromatography

IR infrared TMS tetramethylsilane

TOF time of flight

m multiplet

UV ultraviolet

NBS N-bromosuccinimide

X conversion NCS N-chlorosuccinimide

NMR nuclear magnetic resonance Y yield

Contents

1 Introduction	1
1.1 Hederagonic Acid	1
1.1.1 Natural Occurrence	2
1.1.2 Biological activity	4
1.1.3 Previous syntheses	4
1.2 C-H Activation	7
1.2.1 Stoichiometric C–H Oxidation	7
1.2.1.1 Baldwin's Cyclopalladation Reaction	7
1.2.2 Catalytic C–H Oxidation	10
1.2.2.1 Palladium Catalysed C–H Acetoxylation	10
2 Results and Discussion	13
2.1 Objectives	13
2.2 Preliminary Results	14
2.2.1 Halolactone Oxime	14
2.2.1.1 Chlorolactone Oxime	14
2.2.2 C-H Activation at position C-23	15
2.2.2.1 Palladium Catalysed C–H Acetoxylation	15
2.2.3 Deacetylation and Deoximation	16
2.2.4 Retro-halolactonisation	17
2.3 Optimisation of the Synthetic Sequence	18
2.3.1 Halolactone Oxime	18
2.3.1.1 Chlorolactone Oxime	18
2.3.1.2 Bromolactone Oxime	23
2.3.2 C-H Activation at position C-23	25
2.3.2.1 Palladium Catalysed C–H Acetoxylation	25
2.3.2.2 Copper Catalysed C–H Hydroxylation	29
2.3.3 Deacetylation and Deoximation	32
2.3.4 Retro-halolactonisation	33
2.4 Final Synthetic Route to Hederagonic Acid	35

	2.4	.1 Economic Considerations	37
	2.5	Summary and Outlook	38
3	Fv	perimental Section	41
		-	
	3.1	General Information	41
	3.2	Experimental Procedures	43
	120	x-Chloro-3 β -hydroxyolean-28,13 β -olide (26a)	43
	12	x-Bromo-3β-hydroxyolean-28,13β-olide (26b)	44
	12	x-Chloro-3-oxo-olean-28,13β-olide (27a)	45
	12	x-Bromo-3-oxo-olean-28,13β-olide (27b)	46
	12	x-Chloro-3-(hydroxyimino)-olean-28,13β-olide (6a)	47
	12	x-Bromo-3-(hydroxyimino)-olean-28,13β-olide (6b)	48
	12	x-Chloro-3-(methoxyimino)-olean-28,13β-olide (29)	49
	23	Acetoxy-3-(acetoxyimino)-12α-chloro-olean-28,13 β -olide (7 a)	50
	23	Acetoxy-3-(acetoxyimino)-12α-bromo-olean-28,13β-olide (7b)	51
	12	α -Bromo-23-hydroxy-3-oxo-olean-28,13 β -olide (8 b)	52
	Не	deragonic acid (23-Hydroxy-3-oxo-olean-12-en-28-oic acid) (1)	53
4	Re	ferences and Notes	55
A	ppeı	ndices	59
A	Di	splay Elements	59
	List	of Figures	59
	List	of Schemes	59
	List	of Tables	60
A	bstr	nets	61
	Abst	ract	61
		mmenfassung	61
		mmemuooung	ΟI

Chapter 1

Introduction

1.1 Hederagonic Acid

Hederagonic acid (23-hydroxy-3-oxo-olean-12-en-28-oic acid) (1) is a naturally occurring pentacyclic triterpenoid based on the oleanane scaffold (Figure 1.1). The molecule is related to hederagenin (2), found in *Hedera helix* (common ivy). [1] Hederagonic acid (1) can in principle be accessed from hederagenin (2) *via* oxidation of the C-3 hydroxy group. The first synthesis of 23-*O*-methyl hederagonic acid methyl ester was reported by Jacobs in 1925. [2] 23-*O*-Methyl hederagonic acid methyl ester was obtained *via* oxidation of 23-*O*-methyl hederagenin with potassium permanganate. [2]




Figure 1.1 | Structure of hederagonic acid (1), hederagenin (2) and the oleanae scaffold with applied atom numbering.

The first reported isolation of hederagonic acid was by Agarwal and Rastogi from *Viburnum erubescens* Wall in 1974.^[3] It should be mentioned here, that the use of the therein proposed name "hederagenic acid" was widely discontinued, as "hederagonic acid" had already been coined as trivial name.^[4]

Like many other oleananes,^[5] hederagonic acid (1) is a sapogenin (aglycon). To this day, isolation of two hederagonic acid saponins, hederagonic acid β -D-glucopyranosyl ester (3),^[6] and nipponoside A (4),^[7] has been reported (Figure 1.2).

Hederagonic acid
$$\beta$$
-D-glucopyranosyl ester (3) $C_{36}H_{56}O_9$ $C_{48}H_{76}O_{18}$ O_{11} O_{11} O_{12} O_{13} O_{14} O_{15} O_{1

Figure 1.2 | Structure of hederagonic acid saponins.

1.1.1 Natural Occurrence

Hederagonic acid is found in several other plant species besides *Viburnum erubescens*. In 1993, Greca *et al.* reported its isolation from *Hydrocotyle ranunculoides* (floating pennywort), ^[8] documented as an invasive species. ^[9] In 2012, Li *et al.* detected hederagonic acid as a metabolite in *Celastrus orbiculatus* (oriental bittersweet), ^[10] native to China, ^[10] and also an invasive species. ^[11] In 2012, Yao *et al.* isolated hederagonic acid (1) alongside its saponin hederagonic acid β-D-glucopyranosyl ester (3) from *Kalopanax septemlobus* (castor aralia), ^[6] a plant species native to eastern Asia, China, Japan, Korea and eastern coastal Russia. ^[12] Further species reported to contain hederagonic acid are *Pulsatilla chinensis*, ^[13] *Pulsatilla cernua*, ^[14] and *Tripterygium wilfordii* (thunder god vine). ^[15] Miyakoshi *et al.* isolated the saponin nipponoside A (4) from *Acanthopanax nipponicus*. ^[7] Some selected plant species are depicted in Figure 1.3.




Figure 1.3 | Selected plants containing hederagonic acid (1).

1.1.2 Biological activity

It has been reported, that hederagonic acid (1) and other triterpenoids arjunolic acid, bayogenin and 4-epi-hederagonic acid were moderate glycogen phosphorylase inhibitors. [18,19] Hederagonic acid (1) was the most potent inhibitor with an IC_{50} of 54 μ mol l^{-1} . Notably, 4-epi-hederagonic acid was the second most active inhibitor with an IC_{50} of 62 μ mol l^{-1} . The IC_{50} values of the other examined triterpenoids were 68 μ mol l^{-1} for bayogenin, and 103 μ mol l^{-1} for arjunolic acid.

Furthermore, hederagonic acid (1) exhibited moderate cytotoxicity against several cell lines in biological studies. Considering the IC $_{50}$ values, hederagonic acid (1) was among the most active compounds when compared with other triterpenoids, such as betulinic acid, hederagenin (2), 23-hydroxybetulinic acid, oleanolic acid (5) and ursolic acid. With an IC $_{50}$ of 13.02 µg ml $^{-1}$, hederagonic acid (1) was the second most active compound against SMMC-7721 hepato carcinoma cells, and was fount to have the highest inhibitory effect against HeLa uterocervical carcinoma cells with an IC $_{50}$ of 11.88 µg ml $^{-1}$ and against HL-60 leukocythemia carcinoma cells with an IC $_{50}$ of 14.35 µg ml $^{-1}$.

1.1.3 Previous syntheses

To date, the first and only semisynthesis of hederagonic acid (1) was reported by Wen *et al.* in 2010.^[18] The 9-step synthesis starts from oleanolic acid (5), a natural product found in a wide variety of plants.^[20] The synthetic route begins with a stepwise benzylation-oxidation-oximation sequence reported by Chen *et al.*^[21] After formation of the benzylester of oleanolic acid, pyridinium chlorochromate (PCC) is used to oxidise the secondary C-3 alcohol. The ketone intermediate is then treated with hydroxylamine hydrochloride to give the corresponding **6c** (Scheme 1.1).

Scheme 1.1 | Steps 1–3 of the hederagonic acid (1) semisynthesis reported by Wen *et al.*

Introduction of the C-23 hydroxy group was achieved in 3 steps, utilising Baldwin's stoichiometric cyclopalladation reaction (Scheme 1.2). The intermediate **7c** was obtained as a mixture of diastereomers, which could be separated later in the sequence. The details of this cyclopalladation method are described in Section 1.2.1.

Scheme 1.2 | Steps 4–6 of the hederagonic acid (1) semisynthesis reported by Wen *et al.*

The synthesis was finished by a 3-step deprotection series, starting with the deacetylation of O-23 using sodium carbonate in MeOH. At that point the cyclopalladation by-product (In effect a precursor to 4-epi-hederagonic acid) was separated *via* column chromatography. Subsequent C-3 deoximation with titanium(III) chloride and water gave ketoalcohol benzylester **8c**, which was finally debenzylated by palladium catalysed hydrogenolysis to yield the target molecule **1** (Scheme 1.3).

Scheme 1.3 | Steps 7–9 of the hederagonic acid (1) semisynthesis reported by Wen *et al.*

A major drawback of this synthesis is the high number of steps combined with the utilisation of stoichiometric amounts of expensive and toxic palladium(II) and lead(IV) compounds for the introduction of the hydroxy group at C-23. Furthermore, the reported synthesis relies on the carcinogenic chromium(VI) reagent PCC for the oxidation of the C-3 hydroxy group. Last but not least, the choice of a benzyl protection resulted in a fair yield for the final deprotection.

1.2 C-H Activation

1.2.1 Stoichiometric C-H Oxidation

1.2.1.1 Baldwin's Cyclopalladation Reaction

In 1985, Baldwin *et al.* described a method for an oxime directed functionalisation of unactivated primary sp³ carbons.^[22] These authors investigated the reactivity of the organopalladium species **10** and **11**. The dimer **10** was prepared from pinacolone oxime (**9**) *via* treatment with stoichiometric amounts of NaOAc and Na₂[PdCl₄] in MeOH as described by Constable *et al.*^[23] Constable *et al.* have further described the formation of monomeric bridge-split derivatives (**11**). These were obtained *via* reaction with pyridine, PMe₂Ph or PPh₃. Baldwin *et al.* investigated the oxidation of the dimeric species **10** and the monomeric pyridine complex **11a** with Pb(OAc)₄. While the former did not react with Pb(OAc)₄, the latter was readily oxidised with Pb(OAc)₄ at room temperature, giving different products depending on the amount of oxidant used. Their findings indicated that treatment with 1 equiv and 2 equiv of oxidant yielded acetoxylated oxime **12** and acetoxylated ketone **13**, respectively (Scheme 1.4). To prevent recomplexation of Pd^{II} with products bearing an oxime moiety, the Pb(OAc)₄ promoted oxidation was followed by reduction of Pd^{II} to Pd⁰ with NaBH₄.

Scheme 1.4 | Stoichiometric C–H bond oxidation. (A) The synthesis of monomeric palladacycle **11**. (B) Baldwin's cyclopalladation method.

Baldwin's cyclopalladation reaction has found wide application in the synthesis and modification of natural products and their analogues. Baldwin *et al.* used it for derivatisation of the triterpene lupanone (**14**) (Scheme 1.5a). [22] Carr *et al.* used the method to introduce a hydroxy group at C-23 of lanostenone (**16**), enabling 4α -demethylation to obtain 4β -demethyl-lanostenone (**17**) (Scheme 1.5b). [24] Peakman *et al.* applied Baldwin's method for the introduction of a hydroxy group at C-23 of ursenone oxime, oleanenone oxime and lupanone oxime. [25] Bore *et al.* have utilised it in the transformation of ursolic acid (**18**) into β -boswellic acid analogues (**19a,b**) (Scheme 1.5c). [26] Finally, as described in Section 1.1.3, Wen *et al.* have employed this method for introduction of the C-23 hydroxy group in their semisynthesis of hederagonic acid (**1**) (Scheme 1.5d). [18]

b | Carr et al.

Lanostenone (16)

4β -Demethyl-lanostenone (17)

c | Bore *et al.*

Ursolic acid (18)

Boswellic acid derivatives (19)

d | Wen et al.

Oleanolic acid (5)

Scheme 1.5 | Selected applications of Baldwin's cyclopalladation reaction.

1.2.2 Catalytic C-H Oxidation

1.2.2.1 Palladium Catalysed C-H Acetoxylation

In 2004, Sanford and coworkers reported a modified version of Baldwin's method.^[27] This modification utilises catalytic palladium in combination with stoichiometric amounts of an oxidant at elevated temperatures (80 to 100 °C). In the original publication, Sanford and coworkers employed (Diacetoxyiodo)benzene (PhI(OAc)₂), however, application of other oxidants such as Oxone has been reported.^[28]

In their initial studies, Sanford and coworkers investigated the C–H acetoxylation of pinacolone *O*-methyl oxime (**20**).^[27] They were able to mimic Balwin's method with 5 mol % of Pd(OAc)₂ and 1.1 equiv of PhI(OAc)₂. However, they obtained a mixture of mono-, di-, and tri-acetoxylated *O*-methyl oximes **22a–c**. They propose a dimeric intermediate **21**, which was oxidatively cleaved by PhI(OAc)₂ to yield the mono-acetoxylated oxime **22a**. Repeated acetoxylation of **22a** lead to di- and tri-acetoxylated oximes **22b,c**.

Scheme 1.6 | Catalytic C–H bond oxidation reported by Sanford and coworkers.

These authors further report on the chemo- and regioselectivity of the developed acetoxylation, demonstrating that primary C–H bonds are favoured over secondary C–H bonds. Furthermore, they showed that acetoxylation takes place exclusively in the β -position. This regioselectivity mirrors the highly favoured formation of 5-membered palladacycles.^[29] Notably, the successful acetoxylation of 2,2-dimethylpentanone *O*-methyl oxime (24), a molecule that Baldwin *et al.* have described as unsuited for application of their method (Scheme 1.7), is reported.^[22]

Scheme 1.7 | Catalytic C–H bond oxidation of 2,2-dimethylpentanone oximes **23** and **24**.

Sanford and coworkers have furthermore conducted mechanistic studies on this palladium catalysed C–H bond oxidation, and propose a catalytic cycle featuring a Pd^{II}/Pd^{IV} redox system. [30,31] The catalytic cycle starts with a chelate-directed C–H bond activation giving a 5-membered palladacycle intermediate. Next, the oxidation of Pd^{II} to Pd^{IV} is facilitated by the stoichiometric oxidant. The catalyst is regenerated via a C–X bond forming reductive elimination, releasing the oxidised product. Both an intramolecular elimination and an intermolecular nucleophilic substitution can facilitate the C–X bond formation. [30]

Scheme 1.8 | Catalytic cycle of the C–H bond oxidation, proposed by Sanford and coworkers.



Chapter 2

Results and Discussion

2.1 Objectives

Hederagonic acid was found to be a suitable starting material for the synthesis of polyhydroxylated triterpenoids. Nevertheless, hederagonic acid is very expensive and has limited commercial availability. Hederagonic acid can be synthetically accessed from oleanolic acid, a cheap and readily available natural product. However, the to date only reported synthesis of hederagonic acid requires 9 steps, starting from oleanolic acid, and utilises stoichiometric amounts of palladium for the C–H oxidation at position C-23 (Section 1.1.3). Addressing these drawbacks, this work aims to provide a shorter and cheaper synthesis of hederagonic acid to enhance the accessibility of hederagonic acid as a starting material for semisyntheses. Furthermore, synthetic intermediates that can serve as a starting point to access further polyhydroxylated triterpenoids were targeted.

Scheme 2.1 | Concise synthesis of hederagonic acid (1) *via* catalytic C–H oxidation.

2.2 Preliminary Results

Part of the results described in this chapter were obtained in collaboration with Martin Berger, MSc. His preliminary results are summarised in Sections 2.2.1–2.2.4.^[32]

2.2.1 Halolactone Oxime

The low yield of the debenzylation step in the synthesis reported by Wen *et al.* (Section 1.1.3) suggested that an alternative protecting group would be necessary. Moreover, Berger found incompatibilities between the C-12 olefin moiety and reaction conditions needed towards the synthesis of terminolic acid (**33d**). These two problems led to the utilisation of a halolactone group, which can be considered as a 2-in-1 protection of the carboxylic acid and the olefin moiety. Due to an increased C–X bond stability and the consequent robustness through the synthetic sequence, [33] the use of a chlorolactone protection was preferred over a bromolactone protection.

2.2.1.1 Chlorolactone Oxime

The synthesis of chlorolactone oxime **6a**, whose oxime moiety acts as the directing group in the subsequent C–H activation (Section 2.2.2), was initially developed by Berger as a sequential 3-step procedure. The first step involved the use of *N*-chlorosuccinimide (NCS) in dimethyl formamide (DMF) at 80 °C (Scheme 2.2). After aqueous workup, the obtained chlorolactone **26a** was used without further purification.

Scheme 2.2 | Synthesis of chlorolactone alcohol **26a**. Reagents and conditions: (i) NCS, DMF, 80 °C, 30 min.

Chlorolactone ketone **27a** was synthesised *via* oxidation of **26a** with PCC in dichloromethane (DCM) at room temperature (Scheme 2.3). To ensure full conversion at short reaction times 2 equiv of PCC were used. As for the lactonisation, this reaction proceeded with excellent selectivity, so that no further purification was necessary.

Scheme 2.3 | Synthesis of chlorolactone ketone **27a**. Reagents and conditions: (iia) PCC, DCM, 20 °C, 3 h.

Subsequent transformation of chlorolactone ketone **27a** to the respective oxime **6a** was achieved by treatment with 2 equiv of hydroxylamine hydrochloride in pyridine at 80 °C (Scheme 2.4). The obtained oxime was used after aqueous workup without further purification.

Scheme 2.4 | Synthesis of chlorolactone oxime **6a**. Reagents and conditions: (iii) Hydroxylamine hydrochloride, pyridine, 80 °C, 90 min.

2.2.2 C-H Activation at position C-23

2.2.2.1 Palladium Catalysed C-H Acetoxylation

The palladium catalysed C–H activation method, described in Section 1.2.2.1, was utilised for the introduction of the hydroxy group at C-23. The conditions used were based on those reported by Neufeldt and Sanford, using PhI(OAc)₂ as the oxidant (Scheme 2.5).^[34] The C–H

acetoxylation method, with substrate controlled stereoselectivity, yielded the acetoxylated molecule 7a as a mixture of diastereomers. Assignment of the diastereomers was established by 1 H-NMR spectroscopy, as described by Hart $et\ al.$ [4]

Scheme 2.5 | C–H Acetoxylation of chlorolactone oxime **6a** as performed by Berger.

2.2.3 Deacetylation and Deoximation

Subsequent deacetylation and deoximation were carried out in a one-pot reaction. First, deacetylation was achieved by treatment of chlorolactone 7a with K_2CO_3 in MeOH. Subsequent deoximation was accomplished by further addition of copper sulfate pentahydrate in water, and tetrahydrofuran (THF). As the previously formed 4-epimer was removed *via* column chromatography, β -hydroxy ketone 8a was obtained as a single diastereomer (Scheme 2.6).

Acon
$$Acon$$
 $Acon$ Ac

Scheme 2.6 | One-pot deacetylation-deoximation of chlorolactone **7a**. Reagents and conditions: See Scheme 2.25 on Page 36.

2.2.4 Retro-halolactonisation

Lewis and Tucker reported that bromolactone alcohol **26b** could be debrominated to yield oleanolic acid (5).^[35] The described reaction utilised zinc in acetic acid (Scheme 2.7).

 $\textbf{Scheme 2.7} \mid \text{Retro-halolactonisation of bromolactone alcohol 26b}, \text{ reported by Lewis and Tucker}.$

Nevertheless, when Berger applied this method to a more complex 3-oxo-chlorolactone intermediate, it was not successful in opening the lactone. Furthermore, he observed the reduction of the C-3 carbonyl during the reaction. Berger also found that treatment of a more complex intermediate with samarium(II) iodide did not yield the desired free acid.

2.3 Optimisation of the Synthetic Sequence

2.3.1 Halolactone Oxime

2.3.1.1 Chlorolactone Oxime

As multiple single steps consume not only more solvents, but also more time during necessary aqueous workup, possible multi-step one-pot reactions are preferred.^[36,37] To optimise the synthesis of chlorolactone oxime **6a** (Section 2.2.1.1) in terms of step economy, the initial 3-step sequence was examined.

Analysing the first two steps, no conflicting reactivity was anticipated between the chlorination by-product, succinimide, and PCC. Furthermore, oxidation with chromium(VI) in DMF has been reported previously.^[38] However, it was found that the oxidation in DMF proceeds much slower. Even when using 3 equiv of oxidant and heating to 80 °C the reaction did not reach full conversion in a less than 24 h. Trace amounts of residual DMF further complicated the removal of chromium(IV) waste-products. When using DCM as solvent, these can normally be removed by precipitation with Et₂O and subsequent filtration through Florisil.^[39] Nevertheless, the use of DCM as alternative solvent was not considered as it does not solubilise oleanolic acid (5).

During screening of further solvents, THF was found to be a suitable substitute. Not only was oleanolic acid (5) soluble, but also the chromium(IV) by-products were easily removable by precipitation with Et_2O . Surprisingly, a new by-product was detected and identified as γ -butyrolactone (GBL), formed via oxidation of THF with PCC (Scheme 2.8). Literature research showed that PCC has never been reported to oxidise THF into GBL. In a control experiment, a solution of THF and PCC in CDCl₃ was prepared. GBL was formed at room temperature, with conversions of 0.5 % after 24 h and 3 % after 12 d.

O PCC
$$0 \times 0$$
 0×0 0×0

Scheme 2.8 | The formation of γ -butyrolactone in the reaction of THF and PCC.

This side reaction did not, however, pose a limitation as the formed γ -butyrolactone could be readily removed *in vacuo* at 80 °C, without decomposing chlorolactone ketone **27a** (Scheme 2.9). The one-pot sequence gave chlorolactone ketone **27a** in quantitative yield.

Scheme 2.9 | One-pot synthesis of chlorolactone ketone **27a**. Reagents and conditions: (II) THF, 60 °C. (a) NCS, 1 h. (b) PCC, 3 h.

Rivero-Chan *et al.* reported that the bromo-analogue of **27a** (Section 2.3.1.2) readily crystallised during isolation. This was also the case for the herein synthesised chlorolactone **27a**. Dissolution in a 1:1 mixture of DCM and Et_2O followed by slow evaporation gave colourless crystals suitable for X-ray analysis. The obtained crystal structure (Figure 2.1) shows that **27a** is a hexacyclic molecule based on the pentacyclic oleanane scaffold. The chlorine atom is tethered to C-12 in an α -axial orientation. The γ -lactone bridges C-17 and C-13 in β -orientation. As expected, the reported bromolactone ketone and the herein synthesised chlorolactone ketone **27a** share the same structural features. Rings A–B, B–C and C–D are *trans*-fused, while rings D–E are *cis*-fused.




Figure 2.1 | Crystal structure of chlorolactone ketone **27a**. Thermal ellipsoids have been drawn at 50 % probability level. Hydrogen atoms were omitted for clarity.

After successful combination of the first two steps, a potential concatenation with the oximation step was next investigated (Scheme 2.10). This task however, proved to be more

challenging. The lower yield of <86 % was most likely attributable to separation problems during aqueous workup. The latter resulted from problems of the removal of chromium by-products. Separation of the heavy metal by-products worked well in the tandem lactonisation-oxidation. Thus, it is probable that the presence of hydroxylamine hydrochloride caused the formation of further reduced chromium compounds. However, attempts to determine the nature of these by-products were unsuccessful. These newly-produced chromium species were soluble in the organic phase and could therefore not be removed by filtration.

Scheme 2.10 | One-pot synthesis of oxime **6a**. Reagents and conditions: (II) THF, 60 °C. (a) NCS, 1 h. (b) PCC, 3 h. (c) Hydroxylamine hydrochloride, pyridine, 5 h.

Numerous attempts were carried out, aiming to remove the chromium impurities. First assays to separate the heavy metal species during aqueous workup failed. Neither acidic nor basic media could remove the chromium. The use of saturated EDTA-Na₂ solution only partially extracted the chromium species. Also, ion exchange resins seemed to have an effect, although they were not capable of fully removing the heavy metal residues. Further attempts to precipitate chlorolactone oxime **6a** with water and isolate the chromium free compound by filtration failed, as the impurities precipitated as well. Recrystallisation also proved to be an inappropriate method, as no solvent system was found, that selectively dissolved either chlorolactone oxime **6a** or the chromium impurities. Furthermore, attempts to bind the chromium already during the reaction were carried out. These included addition of ethylenediaminetetraacetic acid or ion exchange resins to the reaction mixture before hydroxylamine hydrochloride was added. However, none of them was sufficiently binding the chromium. As this issue could not be resolved satisfyingly, the search for alternatives to PCC became necessary.

A recently reported method by Dip *et al.* provided a solution to this problem. Their work demonstrates the selective oxidation of secondary alcohols with trichloroisocyanuric acid (TCCA) (Scheme 2.11), a chemical widely used for swimming pool disinfection.^[41] In the

general procedure a solution of TCCA (0.4 equiv, equals 1.2 equiv Cl^+) in EtOAc was added to a solution of the respective alcohol (1 equiv) in EtOAc at room temperature. Pyridine (1.2 equiv) was added to prevent α -chlorination. Cyanuric acid, the only formed by-product, can be easily removed by filtration. After standard aqueous workup, the product is usually obtained without requirement for further purification.

Scheme 2.11 | The oxidation of secondary alcohols with TCCA, reported by Dip *et al.*

A control experiment was carried out, treating chlorolactone alcohol **26a** in EtOAc with a solution of TCCA in EtOAc. The experiment showed, that this procedure was also suitable for oxidation of the C-3 alcohol in the oleanane scaffold (Scheme 2.12).

Scheme 2.12 | Oxidation of chlorolactone alcohol **26a** with TCCA. Reagents and conditions: (iib) TCCA, pyridine, EtOAc, 20 °C, 3 h.

The use of TCCA would further simplify the reaction setup, as it is not only capable of performing the oxidation, but also enabling the chlorolactonisation.^[42] In principle, 0.8 equiv of TCCA are necessary to achieve this tandem transformation.

Considering a potential consecutive concatenation of the oximation step, the utilisation of TCCA required several adaptations of the reaction conditions. The high reactivity of TCCA towards THF on the one hand, [43] and the poor solubility of the later targeted oxime 6a in neat EtOAc on the other hand, demanded further solvent screening (Table 2.1). Similar conditions as those reported by Dip *et al.* were thereby used as a reference (Entry 1). It was found that

262

concentration plays a crucial role in the chemoselectivity of TCCA. Too high concentrations resulted in the precipitation of chlorolactone ketone **27a**, accompanied by the formation of the α -chlorinated ketone (Entry 2). DCM was therefore added to enhance the solubility of the targeted chlorolactone ketone **27a**, allowing the reaction to be performed at higher concentrations (Entry 3). The later targeted oxime **6a**, however, still remained insoluble in the used mixture of DCM/EtOAc (1:3). Due to the previously mentioned poor solubility of oleanolic acid (**5**) in neat DCM, it was at first not considered as solvent for this reaction, although it sufficiently solubilised the later targeted oxime **6a**. Conveniently, it was found later that addition of pyridine promotes solubilisation of oleanolic acid (**5**) in DCM. Furthermore, it was found that TCCA can be added neat to the reaction mixture when using DCM as solvent, thus, enabling access to chlorolactone ketone **27a** with minimal preparative effort (Entry 4).

Table 2.1 | Solvent screening for the tandem lactonisation-oxidation with TCCA. All reactions were carried out on a 1 mmol scale (1.0 equiv of oleanolic acid (5), 0.8 equiv of TCCA and 2.4 equiv of pyridine) at $20\,^{\circ}$ C.

	20a			27a	
Entry	Solvent	V_n/ml	TCCA addition	Note	
1	EtOAc	16	EtOAc (2 ml)	Quantitative yield	
2	EtOAc	8	EtOAc (2 ml)	5 % α-chlorination	
3	DCM/EtOAc (1:3)	8	DCM/EtOAc (1:3, 4 ml)	Quantitative yield	
4	DCM	12	neat	Quantitative yield	

With these conditions in hand, concatenation of the oximation step was targeted. To prevent formation of highly explosive nitrogen trichloride or chlorination of the oxime moiety, excess TCCA had to be quenched before the addition of hydroxylamine hydrochloride. The secondary alcohol *i*-PrOH was employed as TCCA-scavenger. The optimised procedure consumes 15.2 equiv pyridine, 0.8 equiv TCCA, 0.8 equiv *i*-PrOH and 3.2 equiv hydroxylamine hydrochloride (Scheme 2.13). The whole sequence is carried out at room temperature, requires an overall reaction time of 21 h and affords chlorolactone oxime **6a** in 98 % yield. Nevertheless,

the problems described later in Section 2.3.4 required an inevitable switch to the respective bromolactone.

Scheme 2.13 | Enhanced one-pot synthesis of chlorolactone oxime **6a**. Reagents and conditions: (III) DCM, pyridine, 20 $^{\circ}$ C. (a) TCCA, 90 min, then *i*-PrOH, 30 min. (b) Hydroxylamine hydrochloride, 19 h.

2.3.1.2 Bromolactone Oxime

Kaminskyy *et al.* have previously reported the synthesis of bromolactone oxime **6b** in a 3-step sequence starting from oleanolic acid (**5**) (Scheme 2.14).^[45] First, lactonisation was achieved by treatment of oleanolic acid (**5**) with bromine.^[35] The oxidation was then accomplished *via* reaction of bromolactone alcohol **26b** with chromium trioxide and pyridine. Unfortunately, neither of these steps has reported yields. Treatment with hydroxylamine hydrochloride gave the oxime **6b** in 91 % yield from bromolactone ketone **27b**.

Scheme 2.14 | Synthesis of bromolactone oxime **6b** reported by Kaminskyy *et al.*

Alternative conditions for lactonisation and oxidation have been reported by Elsayed *et al.* and Rivero-Chan *et al.*, respectively. The former used *N*-bromosuccinimide (NBS) to form bromolactone alcohol **26b** in a yield of 76 %. The latter synthesised bromolactone ketone **27b** *via* Jones oxidation. [40]

The herein developed chlorolactone oxime **6a** synthesis, described in Section 2.3.1.1, was adapted to synthesise bromolactone oxime **6b**. Initial considerations suggested the substitution of 0.4 equiv of TCCA with 1.05 equiv of NBS. Interestingly, the first attempts to synthesise bromolactone oxime **6b** according to the adapted sequence failed. Only traces of ketone were formed after addition of TCCA. Comparison of the redox potentials of NCS and TCCA may explain this observation. Due to its higher oxidation potential, [42] TCCA reoxidises the NBS waste-product, succinimide, to NCS (Scheme 2.15).

Scheme 2.15 | Proposed chlorination of succinimide.

A control experiment was carried out to prove this proposal. Treatment of bromolactone alcohol **26b** with NCS did not yield bromolactone ketone **27b** (Scheme 2.16). Hence, 0.35 equiv of TCCA (Equals 1.05 equiv of Cl⁺) are most likely quenched by the formed succinimide, preventing the oxidation of the C-3 hydroxy group. To resolve this issue, the amount of TCCA was increased to 0.8 equiv.

Scheme 2.16 | Oxidation attempt with NCS.

The optimised procedure consumes 15.2 equiv pyridine, 1.05 equiv NBS, 0.8 equiv TCCA, 0.8 equiv i-PrOH and 3.2 equiv hydroxylamine hydrochloride (Scheme 2.17). The whole sequence is carried out at room temperature, requires an overall reaction time of 24 h and affords bromolactone oxime $\bf 6b$ in 99 % yield.

Scheme 2.17 | One-pot synthesis of bromolactone oxime **6b**. Reagents and conditions: See Scheme 2.25 on Page 36.

2.3.2 C-H Activation at position C-23

2.3.2.1 Palladium Catalysed C-H Acetoxylation

In a first reaction series at 80 °C, the influence of the reaction time was examined (Table 2.2, entries 1–3). It was found that decreasing the reaction time from 16 h to 7 h had a beneficial impact on the yield. It was therefore surmised that the product decomposes under the reaction conditions. The low yields of isolated product were not in accordance with the NMR spectra of the crude, as the latter never indicated high amounts of impurities. Nevertheless, each reaction formed high amounts of unidentified black material, which was removed by column chromatography. It was considered that this black material might be decomposed product, prompting an investigation of the effects of lower temperatures on the yield.

At that point, Berger successfully employed the method at 45 °C.^[32] At this temperature, no black material was observed in the reaction mixture. The reaction was thereafter performed at even lower temperatures, however with higher catalyst loadings (Table 2.2, entries 4–7). The general trend observed was that higher *dr* values were obtained at lower temperatures. The highest yield was achieved at 35 °C after 29 h reaction time (Entry 4). No difference in reactivity was observed between the usage of 1.5 equiv and 2.0 equiv of PhI(OAc)₂ (Entries 5 and 6). To test the limits of this reaction another batch was conducted at 20 °C (Entry 7). Intriguingly, the substrate was successfully acetoxylated, but at very slow reaction rates, as expected. Nevertheless, the yield of 34 %, previously achieved at 80 °C was also reached at 20 °C within 48 h (Entries 3 and 7).

Table 2.2 | Screening of the C–H acetoxylation of chlorolactone oxime 6a. All reactions were carried out on a 0.1 mmol scale (1.0 equiv of chlorolactone oxime 6a, 26.5 equiv of Ac_2O) in 0.25 ml of AcOH.

Further investigations were carried out on pre-acetylated chlorolactone oxime 28a (Tables 2.3 and 2.4), prepared by Berger.^[32] This allowed the omission of Ac_2O from the reaction mixture, and therefore enabled the screening of alternative solvent compositions.

MeNO₂ and DCE were examined as alternative solvents. The reactions were set up with and without Ac_2O additive respectively (Table 2.3). Notably, exchanging AcOH for either MeNO₂ or DCE drastically reduced the desired reactivity. Only doubling of the catalyst loading and the amount of oxidant gave a reasonable yield of 19 %, alongside an improved dr of 90:10 (Entry 2).

Reddy *et al.* previously reported a palladium catalysed acetoxylation with $Mn(OAc)_2$ as co-catalyst and Oxone as oxidant.^[28] Several attempts to apply this method have been carried out (Table 2.4). However, only traces of the desired acetoxylated product **7a** were observed (Entries 1, 3 and 4). When the reaction was performed in DCE without Ac_2O , the starting material was recovered (Entry 2).

^a Determined *via* ¹H-NMR spectroscopy.

<5a

80:20

16

0

Table 2.3 | Solvent screening for C–H acetoxylation of chlorolactone *O*-acetyloxime **28a**. All reactions were carried out on a 0.1 mmol scale (1.0 equiv of chlorolactone *O*-acetyloxime **28a**) in 0.5 ml of AcOH at 80 °C.

10

MeNO₂

5

Table 2.4 | Screening of the C–H acetoxylation of chlorolactone *O*-acetyloxime **28a**. All reactions were carried out on a 0.1 mmol scale (1.0 equiv of chlorolactone *O*-acetyloxime **28a**, 0.20 equiv of Pd(OAc)₂, 1.2 equiv of Mn(OAc)₂ and 5.0 equiv of Oxone) in 0.25 ml of solvent at 80 °C.

1.5

^a Determined via ¹H-NMR spectroscopy.

^a Determined via ¹H-NMR spectroscopy.

Further examinations were carried out on *O*-methylated chlorolactone oxime **29a**. C–H Acetoxylation of *O*-methyl oximes has been previously reported by Sanford and coworkers.^[27] The examined chlorolactone *O*-methyl oxime **29a** was synthesised from chlorolactone ketone **27a** *via* oximation with methoxyamine hydrochloride. The C–H acetoxylation of chlorolactone *O*-methyl oxime **29a** was examined in AcOH and DCE (Table 2.5). Neither of the two methods yielded the acetoxylated chlorolactone *O*-methyl oxime **30a**.


Table 2.5 | Screening of the C–H acetoxylation of chlorolactone *O*-methyloxime **29a**. All reactions were carried out on a 0.1 mmol scale (1.0 equiv of *O*-methyloxime **29a**, 0.2 equiv of Pd(OAc)₂ and 1.2 equiv of PhI(OAc)₂) at 75 °C for 8 h.

Due to the issues described later in Section 2.3.4, it was thereafter switched to the respective bromolactone **6b**. Berger slightly modified the C–H acetoxylation conditions described in Table 2.3.^[32] C–H Acetoxylation of bromolactone oxime **6b** was carried out according to the conditions optimised by Berger (Scheme 2.18).

Scheme 2.18 | Synthesis of 7b. Reagents and conditions: See Scheme 2.25 on Page 36.

At last, the correlation between reaction temperature and yield was studied (Table 2.6). Increasing the temperature from 40 °C to 50 °C already resulted in a negative impact on the yield (Entries 2 and 3). Notably, a 20 mmol scale reaction gave a higher yield than a 1 mmol scale reaction (Entries 1 and 2).

Table 2.6 | Screening of the C–H acetoxylation of bromolactone oxime **6b**. All reactions were carried out with $0.15 \, \text{equiv}$ of $Pd(OAc)_2$ and $26 \, \text{equiv}$ of Ac_2O in AcOH (2.5 ml mmol⁻¹) for $16 \, \text{h}$.



^a Determined via ¹H-NMR spectroscopy.

2.3.2.2 Copper Catalysed C-H Hydroxylation

The Schönecker oxidation was examined as alternative method for installation of the C-23 hydroxy group. Successful implementation would shorten the overall synthetic sequence by one step, as no separate directing group cleavage would be needed to generate β -hydroxy ketone **8a**. To apply this method, chlorolactone ketone **27a** had to be transformed into the respective picolylimine **31a** first. Several attempts to employ the procedure recently reported by Baran and coworkers, [47] on chlorolactone ketone **27a** failed.

Initial assumptions that the neighbouring *gem*-dimethyl moiety would sterically hinder the formation of the imine were not confirmed. In fact, a rather fast hydrolysis was the reason why isolation of picolylimine **31a** was unsuccessful. Picolylimine **31a** even hydrolysed rapidly in chloroform, after it was filtered over basic aluminium oxide and stored over molecular sieves.

Measuring NMR samples over solid K_2CO_3 was found to be an appropriate method to slow down hydrolysis.

Adaptation of the procedure described by Baran and coworkers required loading of the Dean-Stark apparatus with activated molecular sieves, and furthermore omission of the aqueous workup (Scheme 2.19). K_2CO_3 was added to quench the reaction. Removal of p-TsOH was achieved by precipitation with dry Et_2O . Inert filtration and subsequent removal of volatiles afforded imine **31a** in quantitative yield. Imine **31a** is stable for several months, if stored dry under an argon atmosphere at +5 $^{\circ}C$.

Scheme 2.19 | Synthesis of picolylimine **31a**. Reagents and conditions: (iv) Dean-Stark apparatus (charged with activated molecular sieves (4 Å)), 2-picolylamine, p-TsOH · H₂O, toluene, reflux, 8 h, then 20 °C, K₂CO₃.

Baran and coworkers optimised the C–H hydroxylation protocol in a mixture of MeOH and acetone. Considering the rapid hydrolysis of picolylimine 31a it is hardly surprising that the compound was not stable under these conditions (Table 2.7, entries 1 and 2). With MeOH as a protic solvent, and acetone as a potential amine scavenger, only hydrolysed ketone 27a was isolated. The effect of added K_2CO_3 and $CaCO_3$, in conjunction with different solvents was examined (Entries 3–8). The desired β -hydroxy ketone 8a was not detected with mass spectroscopy in any of these reactions. Thus, the preparation of β -hydroxy ketone 8a via Schönecker oxidation was not successful.

Table 2.7 | Screening of the Schönecker oxidation. All reactions were carried out on a 0.1 mmol scale (1.0 equiv of picolylimine **31a**, 1.3 equiv of $[Cu(MeCN)_4][PF_6]$, 2.0 equiv of sodium L-ascorbate and O_2 atmosphere) at 50 °C.

Entry	Solvent	V_n/ml	Additive	n(Additive)/equiv	Note
1	MeOH/acetone (1:1)	0.5	_	_	Hydrolysed
2	acetone	0.5	_	_	Hydrolysed
3	MeOH/acetone (1:1)	0.8	K ₂ CO ₃	2.0	Hydrolysed
4	MeOH/acetone (1:1)	0.8	CaCO ₃	2.0	Hydrolysed
5	ACN	0.8	CaCO ₃	2.0	Hydrolysed
6	DMF	0.8	$CaCO_3$	2.0	Hydrolysed
7	DMSO	0.8	$CaCO_3$	2.0	Hydrolysed
8	THF	1.6	CaCO ₃	2.0	Hydrolysed

2.3.3 Deacetylation and Deoximation

Deacetylation and deoximation were carried out in a one-pot reaction as elaborated by Berger (Section 2.2.3), giving β -hydroxy ketone **8b** as a single diastereomer in 55 % yield.

Acon
$$\frac{Br}{H}$$
 $\frac{Br}{H}$ $\frac{Br$

Scheme 2.20 | One-pot deacetylation-deoximation of bromolactone **7b**. Reagents and conditions: See Scheme 2.25 on Page 36.

The low yield of this deprotection prompted further investigations. During examination of reaction conditions, it was found that longer reaction times caused consumption of the desired β -hydroxy ketone **8b**. The newly formed by-product was identified as dehydroxymethylated molecule **32b**, generated in a retro-aldol reaction (Scheme 2.21). This reactivity has been observed previously in 23-hydroxy-3-oxo-oleananes and 24-hydroxy-3-oxo-oleananes. [4,48,49]

Scheme 2.21 | Decarbonylation of β -hydroxy ketone **8b**

Barton and Mayo described the mechanisms for this transformation under acidic as well as under basic conditions.^[48] The herein reported setup features the simultaneous presence of a Lewis acid (Cu²⁺) and a base (CO₃²⁻). Hence, the β -hydroxy ketone can most likely be

dually activated (Scheme 2.22). After elimination of one molecule of formaldehyde, the formed enolate intermediate is protonated to afford the thermodynamically favoured epimer **32b** with α -equatorial conformation.^[4]

Scheme 2.22 | Dually activated retro-aldol formaldehyde elimination.

2.3.4 Retro-halolactonisation

It was not foreseen, that the initial reason for using the chlorolactone – the higher C–X bond energy – would ultimately doom the synthetic route to failure.

Following up the retro-chlorolactonisation attempts by Berger (Section 2.2.4), the suitability of a retro-chlorolactonisation method reported by Soengas *et al.* was examined. Their procedure involves magnesium, zinc chloride and catalytic iodine in THF.^[50] Applied to chlorolactone ketone **27a**, however, this method was not successful. Cleavage of the chlorolactone thus failed with all examined methods (Scheme 2.23 and Section 2.2.4).

Scheme 2.23 | Failed retro-chlorolactonisation of **27a**.

At that point, the choice of halolactone had to be reconsidered. As a result, the synthetic sequence was repeated with the respective bromolactone. Applying the procedure reported by

Lewis and Tucker to bromolactone hydroxyketone **8b** gave the pure target molecule hederagonic acid (**1**) after column chromatography in 95 % yield.

Scheme 2.24 \mid Retro-bromolactonisation of **8b**. Reagents and conditions: See Scheme 2.25 on Page 36.

2.4 Final Synthetic Route to Hederagonic Acid

The following section shortly summarises the complete semisynthesis of hederagonic acid (Scheme 2.25). The synthetic route starts from oleanolic acid (5). Application of the herein described one-pot bromolactonisation-oxidation-oximation sequence affords bromolactone oxime **6b** in 99 % yield. The 3-step one-pot sequence utilises NBS for bromolactonisation, TCCA for oxidation and hydroxylamine hydrochloride for oximation. Intermediate **7b** is accessed *via* one-pot acetylation-acetoxylation. The palladium catalysed C–H acetoxylation gives **7b** as mixture of 4-epimers (dr 75:25) in 48 % yield. β -Hydroxy ketone **8b** is obtained *via* subsequent one-pot deacetylation-deoximation sequence. Deacetylation is accomplished with K_2CO_3 , and deoximation with $CuSO_4$. The undesired 4-epimer was removed *via* column chromatography, giving β -hydroxy ketone **8b** as a single diastereomer in 55 % yield. The final retro-halolactonisation is achieved with zinc in acetic acid, affording the target product **1** in 95 % yield. Hederagonic acid (**1**) is thus synthesised in 4 steps and 20 % overall yield.

Scheme 2.25 | The herein reported semisynthesis of hederagonic acid (1). Reagents and conditions: (1) DCM, pyridine, 20 °C. (a) NBS, 60 min. (b) TCCA, 90 min, then *i*-PrOH, 30 min. (c) Hydroxylamine hydrochloride, 21 h. (2) AcOH, 40 °C. (a) Ac₂O, 2 h. (b) PhI(OAc)₂, Pd(OAc)₂, 16 h. (3) MeOH, 60 °C. (a) K_2CO_3 , 1 h. (b) THF, $CuSO_4 \cdot 5H_2O$ in H_2O , 16 h. (4) Zn, AcOH, 40 °C, 2 h.

2.4.1 Economic Considerations

This work presented a 4-step synthetic route to hederagonic acid (1) starting from oleanolic acid (5). Oleanolic acid can be isolated from the olive tree (*Olea europaea*), a profitable commercial source. While oleanolic acid (5) is available from 134 commercial sources, also on kg scales, hederagonic acid (1) is only offered by 19 commercial sources, and exclusively in mg units. The cheapest offer found for oleanolic acid (5) was from abcr GmbH, with it being available for 816.40 \in per 1 kg. In comparison, the cheapest offer found for hederagonic acid (1) was from MolPort, with 5 mg being available for 513.00 $(436.77 \in -$ Currency conversion on 2017-12-13). Calculating the respective price per amount of substance unveils the vast price difference of these two natural products, with hederagonic acid being approximately 100 000 times more expensive than the same amount of substance of oleanolic acid. The respective values are shown in Figure 2.2. A cheap and straightforward synthesis can possibly lead to an enhanced commercial availability of hederagonic acid (1).




Figure 2.2 | Commercial prices of oleanolic acid (5) and hederagonic acid (1).

2.5 Summary and Outlook

A one-pot reaction was designed for the synthesis of the intermediate oxime. This reaction combines three single steps, and utilises TCCA as oxidant. The one-pot sequence can be carried out at room temperature and affords the intermediate oxime in 99 % yield (1 mmol batch, 97 % in a 20 mmol batch). The use of TCCA allowed omission of commonly used PCC, a known carcinogen. The obtained oxime can be used after aqueous workup, without further purification.

A palladium catalysed C–H acetoxylation at 40 °C was utilised for the introduction of the C-23 hydroxy group. Acetoxylation was even successfully carried out at 20 °C, albeit in low yield. This represents the first example of catalytic C–H acetoxylation at such low temperatures. Furthermore, scalability of this reaction was demonstrated in a 20 mmol batch. As the diastereoselectivity of the C–H acetoxylation is solely substrate controlled, utilisation of chiral ligands could possibly increase the *dr* of this transformation.

The deacetylation-deoximation step may be improved by neutralising excess K_2CO_3 . The absence of base might disfavour the described retro-aldol reactivity. Following this strategy, Berger was able to obtain 65 % yield in this transformation. [32]

In summary, the development of a novel semisynthetic approach to hederagonic acid (1) was presented. Deployment of carefully designed one-pot reactions allowed the shortening of the synthetic sequence, resulting in the to date shortest route to hederagonic acid (1).

At last, the herein synthesised β -hydroxy ketone intermediate $\mathbf{8b}$ could serve as branching point for the syntheses of more complex oleananes (Scheme 2.26). As example, further functionalisation at C-2 can lead to arjunolic acid (33a) and bayogenin (33b). [18] Potential modifications at C-6 would allow access to higher members of the oleanane family, like uncargenin C (33c) and terminolic acid (33d). The versatile biological activities of these natural products, combined with their utterly limited commercial availability, makes them interesting targets in natural product synthesis.

Scheme 2.26 | β -Hydroxy ketone **8b** as potential branching point for routes to higher members of the oleanane family (33a-d).



Chapter 3

Experimental Section


3.1 General Information

Glassware and Techniques: Unless otherwise indicated, no glassware was flame dried before use, and all reactions were performed under an air atmosphere, not using standard Schlenktechniques. Reagents and Solvents: Unless otherwise stated, all reagents and solvents were used as received from commercial suppliers. Reaction Monitoring: Reaction progress was monitored using thin layer chromatography (TLC) on aluminium sheets coated with silica gel 60 with 0.2 mm thickness (Pre-coated TLC-sheets ALUGRAM[®] Xtra SIL G/UV₂₅₄). Visualisation was achieved either by UV light (254 nm and 363 nm), by treatment with potassium permanganate and heat, or by treatment with ethanolic phosphomolybdic acid and heat. Column Chromatography: Flash column chromatography was performed using silica gel 60 (230 to 400 mesh, Merck and co.). NMR Spectra: All NMR spectra were recorded on Bruker Avance III 600 or Avance III 700 spectrometers. Chemical shifts (δ) were given in ppm, referenced to the peak of tetramethylsilane (TMS), using residual non-deuterated solvent as internal standard (1 H: δ (CDCl₃) = 7.26 ppm; 13 C: δ (CDCl₃) = 77.16 ppm). [55] Coupling constants (\mathcal{J}) were quoted in Hz. Spectroscopy splitting patterns were designated as singlet (s), doublet (d), triplet (t), quartet (q), quintet (quint), or combinations thereof. Splitting patterns that could not be interpreted or easily visualised were designated as multiplet (m). Mass Spectra: Mass spectra were obtained using a Bruker maXis spectrometer with ESI-TOF. IR Spectra: Neat infra-red spectra were recorded using a Perkin-Elmer Spectrum 100 FT-IR spectrometer. Wavenumbers (\tilde{v}) were reported in cm⁻¹. **Optical rotation:** Specific rotation $([\alpha]_D^{20})$ was determined on a SCHMIDT+HAENSCH UniPol L 2000 polarimeter at 589.44 nm (sodium D line) in a cell with 100 mm path length. $[\alpha]_D^{20}$ values were reported in 10^{-1} deg cm² g⁻¹. **X-Ray** Analysis: The X-ray intensity data were measured on a Bruker D8 Venture diffractometer equipped with multilayer monochromator, Cu-K_α INCOATEC micro focus sealed tube and Oxford cooling device. The structure was solved by direct methods and refined by full-matrix least-squares techniques. Non-hydrogen atoms were refined with anisotropic displacement parameters. Hydrogen atoms were inserted at calculated positions and refined with a riding

model. The following software was used: Bruker SAINT software package using a narrow-frame algorithm for frame integration,^[56] SADABS for absorption correction,^[57] OLEX2 for structure solution, refinement, molecular diagrams and graphical user-interface,^[58] ShelXle for refinement and graphical user-interface,^[59] SHELXS-2013 for structure solution,^[60] SHELXL-2013 for refinement,^[59] Platon for symmetry check,^[61] mercury for image compilation.^[62]

3.2 Experimental Procedures

12α-Chloro-3β-hydroxyolean-28,13β-olide (26a)




A round bottom flask, equipped with magnetic stirring bar, was charged with a solution of oleanolic acid (5) (10.0 mmol, 4660 mg, 1 equiv) in dry THF (40 ml). After addition of NCS (10.5 mmol, 1402 mg, 1.05 equiv), the flask was immersed into a preheated oilbath (60 $^{\circ}$ C) and the reaction was left stirring at 60 $^{\circ}$ C for 60 min. After cooling to room temperature, the solution was diluted with EtOAc (500 ml) and washed with Na₂S₂O₃ solution (0.1 m in H₂O)

and H_2O (9:1) (250 ml), followed by NaHCO₃ solution (saturated in H_2O) (250 ml). After drying over MgSO₄ the solution was concentrated under reduced pressure. The residue was dried *in vacuo* to give the target compound as pale yellow solid (quantitative yield). The obtained product was used without further purification.

¹H-NMR (600 MHz, CDCl₃): δ4.20–4.16 (m, 1 H, H¹²), 3.25 (dd, $\mathcal{J} = 11.6, 4.5$ Hz, 1 H, H³), 2.25 (ddd, $\mathcal{J} = 13.9, 12.1, 3.2$ Hz, 1 H, H^{11a}), 2.20–2.11 (m, 2 H, H^{16a,19a}), 2.05–1.98 (m, 2 H, H^{5,19a}), 1.94 (td, $\mathcal{J} = 13.7, 6.1$ Hz, 1 H, H^{15a}), 1.78–1.51 (m, 9 H, H^{1a,2ab,6a,7a,11b,18,22ab}), 1.47–1.41 (m, 1 H, H^{6b}), 1.39 (s, 3 H, H²⁷), 1.38–1.32 (m, 1 H, H^{21a}), 1.32–1.24 (m, 3 H, H^{7b,16b,21b}), 1.24–1.17 (m, 4 H, H^{15b,26}), 1.04 (td, $\mathcal{J} = 13.2, 3.6$ Hz, 1 H, H^{1b}), 0.99 (s, 6 H, H^{23,29}), 0.90 (s, 3 H, H³⁰), 0.88 (s, 3 H, H²⁵), 0.80–0.76 (m, 4 H, H^{5,24}); ¹³C-NMR (150 MHz, CDCl₃): δ179.3 (C²⁸), 91.8 (C¹³), 78.9 (C³), 65.2 (C¹²), 55.3 (C⁵), 52.1 (C¹⁸), 45.4 (C¹⁷), 44.9 (C⁹), 43.1 (C¹⁴), 42.5 (C⁸), 39.9 (C¹⁹), 39.0 (C⁴), 38.6 (C¹), 36.6 (C¹⁰), 34.6 (C⁷), 34.0 (C²¹), 33.4 (C²⁹), 32.0 (C²⁰), 29.7 (C¹¹), 29.1 (C¹⁵), 28.1 (C²³), 27.6 (C²²), 27.3 (C²), 23.8 (C³⁰), 21.4 (C¹⁶), 20.3 (C²⁷), 19.0 (C²⁶), 17.8 (C⁶), 16.9 (C²⁵), 15.5 (C²⁴); [α]_D²⁰ +56.5 (c 1.0, CDCl₃); IR (neat) 2932, 2867, 1768, 1713, 1467, HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd for C₃₀H₄₇ClNaO₃⁺ 513.3106; Found 513.3106;

12α-Bromo-3β-hydroxyolean-28,13β-olide (26b)




A round bottom flask, equipped with magnetic stirring bar, was charged with a solution of oleanolic acid (5) (1.00 mmol, 457 mg, 1.00 equiv) in DCM (12 ml) and pyridine (15.2 mmol, 1229 μ l, 15.2 equiv). After addition of NBS (1.05 mmol, 187 mg, 1.05 equiv), the reaction was left stirring at 20 °C for 60 min. Then *i*-PrOH (1.60 mmol, 122 μ l, 1.60 equiv) was added, and the mixture was left stirring at 20 °C for 30 min. The solution was subsequently diluted

with DCM (20 ml) and washed with HCl solution (1 m in H_2O) (32 ml). The aqueous phase was extracted with DCM (2 × 16 ml). The combined organic layers were washed with NaOH solution (1 m in H_2O) (32 ml), followed by NH₄Cl solution (half-saturated in H_2O) (16 ml). After drying over MgSO₄ the solution was concentrated under reduced pressure. The residue was dried *in vacuo* to give the target compound as pale yellow solid (quantitative yield). The obtained product was used without further purification. The spectroscopic data is in accordance with the literature. [35,63]

¹H-NMR (600 MHz, CDCl₃): δ 4.30 (dd, $\mathcal{J} = 3.6, 2.4$ Hz, 1 H, H¹²), 3.26 (dd, $\mathcal{J} = 11.6, 4.4$ Hz, 1 H, H³), 2.40–2.31 (m, 2 H, H^{11a,19a}), 2.16 (td, $\mathcal{J} = 13.4, 5.7$ Hz, 1 H, H^{16a}), 2.04–1.92 (m, 3 H, H^{15a,18,19a}), 1.85 (dt, $\mathcal{J} = 15.0, 2.3$ Hz, 1 H, H^{11b}), 1.77–1.73 (m, 1 H, H⁹), 1.72–1.60 (m, 5 H, H^{1a,2ab,22ab}), 1.60–1.51 (m, 2 H, H^{6a,7a}), 1.47–1.40 (m, 4 H, H^{6b,27}), 1.40–1.24 (m, 4 H, H^{7b,16a,21ab}), 1.23–1.17 (m, 4 H, H^{15b,26}), 1.11–1.04 (m, 1 H, H^{1b}), 1.00 (s, 6 H, H^{23,29}), 0.90 (s, 3 H, H³⁰), 0.88 (s, 3 H, H²⁵), 0.79 (dd, $\mathcal{J} = 12.1, 1.7$ Hz, 1 H, H⁵), 0.77 (s, 3 H, H²⁴); ¹³C-NMR (150 MHz, CDCl₃): δ 179.1 (C²⁸), 91.8 (C¹³), 78.8 (C³), 56.6 (C¹²), 55.3 (C⁵), 52.5 (C¹⁸), 45.7 (C⁹), 45.5 (C¹⁷), 43.5 (C¹⁴), 42.5 (C⁸), 40.1 (C¹⁹), 39.0 (C⁴), 38.4 (C¹), 36.7 (C¹⁰), 34.7 (C⁷), 34.0 (C²¹), 33.4 (C²⁹), 32.0 (C²⁰), 30.6 (C¹¹), 29.3 (C¹⁵), 28.1 (C²³), 27.6 (C²²), 27.3 (C²), 23.7 (C³⁰), 21.4 (C¹⁶), 21.3 (C²⁷), 19.2 (C²⁶), 17.8 (C⁶), 17.1 (C²⁵), 15.5 (C²⁴); [α]_D²⁰ +66.6 (c 1.0, CDCl₃); HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd for C₃₀H₄₇BrNaO₃⁺ 557.2601; Found 557.2591;

12α-Chloro-3-oxo-olean-28,13β-olide (27a)




A round bottom flask, equipped with magnetic stirring bar, was charged with a suspension of oleanolic acid (5) (1.00 mmol, 457 mg, 1.00 equiv) in EtOAc (16 ml) and pyridine (2.40 mmol, 194 μ l, 2.40 equiv). After addition of a solution of trichloroisocyanuric acid (0.80 mmol, 186 mg, 0.80 equiv) in EtOAc (2 ml) the mixture was left stirring at 20 °C for 2 h. The solution was filtered over a glass frit (P 16) and the residue was washed with EtOAc (2 ml). The organics

were washed with HCl solution (1 m in H_2O) (5 ml), NaHCO₃ solution (saturated in H_2O) (5 ml) and NaCl solution (saturated in H_2O) (5 ml). After drying over MgSO₄ the solution was concentrated under reduced pressure. The residue was dried *in vacuo* to give the target compound as colourless foam (quantitative yield).

¹H-NMR (600 MHz, CDCl₃): δ4.19 (dd, $\mathcal{J} = 3.8, 2.4$ Hz, 1 H, H¹²), 2.50 (dd, $\mathcal{J} = 8.7, 6.4$ Hz, 2 H, H²), 2.30 (ddd, $\mathcal{J} = 14.7, 12.6, 3.8$ Hz, 1 H, H^{11a}), 2.20–2.13 (m, 2 H, H^{16a,19a}), 2.06–1.99 (m, 2 H, H^{18,19b}), 1.99–1.89 (m, 2 H, H^{1a,15a}), 1.85 (dd, $\mathcal{J} = 12.6, 2.0$ Hz, 1 H, H⁹), 1.74 (dt, $\mathcal{J} = 14.8, 2.2$ Hz, 1 H, H^{11b}), 1.65 (dd, $\mathcal{J} = 9.0, 3.5$ Hz, 2 H, H^{22ab}), 1.62–1.44 (m, 5 H, H^{1b,5,6ab,7a}), 1.40 (s, 3 H, H²⁷), 1.38–1.32 (m, 2 H, H^{21ab}), 1.32–1.26 (m, 2 H, H^{7b,16b}), 1.24 (s, 4 H, H^{15b,26}), 1.10 (s, 3 H, H²³), 1.04 (s, 3 H, H²⁴), 1.00 (s, 3 H, H²⁹), 0.97 (s, 3 H, H²⁵), 0.91 (s, 3 H, H³⁰); ¹³C-NMR (150 MHz, CDCl₃): δ 217.8 (C³), 179.1 (C²⁸), 91.7 (C¹³), 65.0 (C¹²), 54.6 (C⁵), 52.1 (C¹⁸), 47.3 (C⁴), 45.4 (C¹⁷), 44.2 (C⁹), 43.2 (C¹⁴), 42.3 (C⁸), 39.9 (C¹⁹), 39.4 (C¹), 36.3 (C¹⁰), 34.0 (C²¹), 34.0 (C²), 33.9 (C⁷), 33.4 (C²⁹), 32.0 (C²⁰), 29.9 (C¹¹), 29.1 (C¹⁵), 27.6 (C²²), 27.1 (C²³), 23.7 (C³⁰), 21.4 (C¹⁶), 21.1 (C²⁴), 20.2 (C²⁷), 19.2 (C⁶), 18.6 (C²⁶), 17.0 (C²⁵); [α]_D²⁰ +76.4 (c 1.0, CDCl₃); IR (neat) 2953, 2867, 1776, 1704, 1463, HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd for C₃₀H₄₅ClNaO₃⁺ 511.2949; Found 511.2949;

12α-Bromo-3-oxo-olean-28,13β-olide (27b)




A round bottom flask, equipped with magnetic stirring bar, was charged with a solution of oleanolic acid (5) (1.00 mmol, 457 mg, 1.00 equiv) in DCM (12 ml) and pyridine (15.2 mmol, 1229 μ l, 15.2 equiv). After addition of NBS (1.05 mmol, 187 mg, 1.05 equiv), the reaction was left stirring at 20 °C for 60 min. Subsequently, trichloroisocyanuric acid (0.80 mmol, 186 mg, 0.80 equiv) was added, and the mixture was left stirring at 20 °C for 90 min. Then *i*-PrOH (1.60 mmol,

122 μ l, 1.60 equiv) was added, and the mixture was left stirring at 20 °C for 30 min. The solution was diluted with DCM (12 ml), filtered over a glass frit (P 16) and the residue was washed with DCM (2 × 4 ml). The organics were washed with HCl solution (1 m in H₂O) (32 ml). The aqueous phase was extracted with DCM (2 × 16 ml). The combined organic layers were washed with NaOH solution (1 m in H₂O) (32 ml), followed by NH₄Cl solution (half-saturated in H₂O) (16 ml). After drying over MgSO₄ the solution was concentrated under reduced pressure. The residue was dried *in vacuo* to give the target compound as pale yellow foam (quantitative yield). The obtained product was used without further purification. The spectroscopic data is in accordance with the literature. [35,40]

¹H-NMR (600 MHz, CDCl₃): δ 4.30 (t, $\mathcal{J} = 2.5$ Hz, 1 H, H¹²), 2.55–2.46 (m, 2 H, H²), 2.42 (ddd, $\mathcal{J} = 14.8$, 12.5, 3.7 Hz, 1 H, H^{11a}), 2.33 (dd, $\mathcal{J} = 25.7$, 15.2 Hz, 1 H, H^{19a}), 2.17 (dt, $\mathcal{J} = 13.4$, 5.6 Hz, 1 H, H^{16a}), 2.06–1.86 (m, 5 H, H^{1a,9,15a,18,19b}), 1.84 (bd, $\mathcal{J} = 14.9$ Hz, 1 H, H^{11b}), 1.67–1.57 (m, 4 H, H^{1b,7a,22}), 1.53 (dd, $\mathcal{J} = 12.9$, 2.0 Hz, 1 H, H^{6b}), 1.52–1.41 (m, 5 H, H^{5,6a,27}), 1.39–1.32 (m, 2 H, H²¹), 1.32–1.19 (m, 6 H, H^{7b,15b,16b,26}), 1.10 (s, 3 H, H²³), 1.04 (s, 3 H, H²⁴), 1.00 (s, 3 H, H²⁹), 0.96 (s, 3 H, H²⁵), 0.90 (s, 3 H, H³⁰); ¹³C-NMR (150 MHz, CDCl₃): δ 217.9 (C³), 179.0 (C²⁸), 91.8 (C¹³), 56.3 (C¹²), 54.6 (C⁵), 52.5 (C¹⁸), 47.3 (C⁴), 45.6 (C¹⁷), 44.9 (C⁹), 43.6 (C¹⁴), 42.4 (C⁸), 40.1 (C¹⁹), 39.2 (C¹), 36.4 (C¹⁰), 34.1 (C⁷), 34.0 (C²¹), 33.9 (C²), 33.4 (C³⁰), 32.0 (C²⁰), 31.0 (C¹¹), 29.3 (C¹⁵), 27.6 (C²²), 27.1 (C²³), 23.7 (C²⁹), 21.4 (C¹⁶), 21.1 (C²⁷), 21.0 (C²⁴), 19.2 (C⁶), 18.8 (C²⁶), 17.2 (C²⁵); [α]_D²⁰ +84.0 (c 1.0, CDCl₃); HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd for C₃₀H₄₅ClNaO₃⁺ 555.2444; Found 555.2439;

12α-Chloro-3-(hydroxyimino)-olean-28,13β-olide (6a)




A round bottom flask, equipped with magnetic stirring bar, was charged with a solution of oleanolic acid (5) (1.00 mmol, 457 mg, 1.00 equiv) in DCM (12 ml) and pyridine (15.2 mmol, 1229 μ l, 15.2 equiv). After addition of trichloroisocyanuric acid (0.80 mmol, 186 mg, 0.80 equiv) was added, and the mixture was left stirring at 20 °C for 90 min. Then *i*-PrOH (0.80 mmol, 61 μ l, 0.80 equiv) was added, and the mixture was left stirring

at 20 °C for 30 min. Subsequently, hydroxylamine hydrochloride (3.2 mmol, 222 mg, 3.2 equiv) was added, and the reaction was left stirring at 20 °C for 19 h. The solution was diluted with DCM (8 ml), filtered over a glass frit (P 16) and the residue was washed with DCM (2 × 2 ml). The organics were washed with HCl solution (1 m in H_2O) (3 × 12 ml). After drying over MgSO₄ the solution was concentrated under reduced pressure. The residue was dried *in vacuo* to give the target compound as pale yellow solid (0.98 mmol, 495 mg, 98 %).

¹H-NMR (600 MHz, CDCl₃): δ 7.51 (s, 1 H, H^{3-NOH}), 4.18 (dd, \mathcal{J} = 3.9, 2.3 Hz, 1 H, H¹²), 2.97 (ddd, \mathcal{J} = 15.5, 6.1, 4.2 Hz, 1 H, H^{2a}), 2.37–2.24 (m, 2 H, H^{2b,11a}), 2.19–2.12 (m, 2 H, H^{16a,19a}), 2.02 (d, \mathcal{J} = 9.1 Hz, 2 H, H^{18,19b}), 1.95 (td, \mathcal{J} = 13.7, 6.1 Hz, 1 H, H^{15a}), 1.83–1.72 (m, 3 H, H^{1a,9,11b}), 1.64 (dd, \mathcal{J} = 9.0, 3.5 Hz, 2 H, H^{22a}), 1.61–1.45 (m, 3 H, H^{7a,6ab}), 1.40–1.26 (m, 7 H, H^{7b,16b,21ab,27}), 1.25–1.19 (m, 5 H, H^{1b,15b,26}), 1.18–1.14 (m, 4 H, H^{5,23}), 1.06 (s, 3 H, H²⁴), 0.99 (s, 3 H, H²⁹), 0.98 (s, 3 H, H²⁵), 0.90 (s, 3 H, H³⁰); ¹³C-NMR (150 MHz, CDCl₃): δ 179.2 (C²⁸), 167.1 (C³), 91.7 (C¹³), 65.1 (C¹²), 55.4 (C⁵), 52.1 (C¹⁸), 45.4 (C¹⁷), 44.5 (C⁹), 43.2 (C¹⁴), 42.5 (C⁸), 40.3 (C⁴), 39.9 (C¹⁹), 38.6 (C¹), 36.7 (C¹⁰), 34.2 (C⁷), 34.0 (C²¹), 33.4 (C²⁹), 32.0 (C²⁰), 29.7 (C¹¹), 29.1 (C¹⁵), 27.6 (C²³), 27.6 (C²²), 23.8 (C³⁰), 23.0 (C²⁴), 21.4 (C¹⁶), 20.2 (C²⁷), 18.8 (C²⁶), 18.6 (C⁶), 16.9 (C²), 16.7 (C²⁵); [α]_D²⁰ +27.0 (c 1.0, CDCl₃); IR (neat) 3268, 2930, 2866, 1768, 1464, HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd for C₃₀H₄₆ClNNaO₃⁺ 526.3058; Found 526.3059;

12α-Bromo-3-(hydroxyimino)-olean-28,13β-olide (6b)




A round bottom flask, equipped with magnetic stirring bar, was charged with a solution of oleanolic acid (5) (1.00 mmol, 457 mg, 1.00 equiv) in DCM (12 ml) and pyridine (15.2 mmol, 1229 μ l, 15.2 equiv). After addition of NBS (1.05 mmol, 187 mg, 1.05 equiv), the reaction was left stirring at 20 °C for 60 min. trichloroisocyanuric acid (0.80 mmol, 186 mg, 0.80 equiv) was added subsequently, and the mixture was left stirring at 20 °C for

90 min. Then *i*-PrOH (1.60 mmol, 122 µl, 1.60 equiv) was added, and the mixture was left stirring at 20 °C for 30 min. Subsequently, hydroxylamine hydrochloride (3.2 mmol, 222 mg, 3.2 equiv) was added, and the reaction was left stirring at 20 °C for 21 h. Afterwards, the solution was diluted with DCM (12 ml), filtered over a glass frit (P 16) and the residue was washed with DCM (2 × 4 ml). The organics were washed with HCl solution (1 m in H_2O) (32 ml). The aqueous phase was extracted with DCM (2 × 16 ml). The combined organic layers were washed with NaOH solution (1 m in H_2O) (32 ml), followed by NH₄Cl solution (half-saturated in H_2O) (16 ml). After drying over MgSO₄ the solution was concentrated under reduced pressure. The residue was dried *in vacuo* to give the target compound as pale yellow solid (0.99 mmol, 555 mg, 99 %). The obtained product was used without further purification. In a 20 mmol scale the target compound was obtained in 97 % yield. The spectroscopic data is in accordance with the literature. [45]

¹H-NMR (600 MHz, CDCl₃): δ7.83 (s, 1 H, H^{3-NOH}), 4.30 (t, \mathcal{J} = 2.9 Hz, 1 H, H¹²), 2.97 (ddd, \mathcal{J} = 15.5, 6.1, 4.1 Hz, 1 H, H^{2a}), 2.44–2.29 (m, 3 H, H^{2b,11a,19a}), 2.16 (td, \mathcal{J} = 13.4, 5.7 Hz, 1 H, H^{16a}), 2.05–1.92 (m, 3 H, H^{15a,18,19b}), 1.84 (d, \mathcal{J} = 15.2 Hz, 1 H, H^{11b}), 1.82–1.77 (m, 2 H, H^{1a,9}), 1.64 (dd, \mathcal{J} = 9.3, 3.5 Hz, 2 H, H^{22ab}), 1.61–1.44 (m, 3 H, H^{6ab,7a}), 1.43 (s, 3 H, H²⁷), 1.39–1.31 (m, 2 H, H^{21ab}), 1.31–1.19 (m, 7 H, H^{1b,7b,15b,16b,26}), 1.19–1.14 (m, 4 H, H^{5,23}), 1.06 (s, 3 H, H²⁴), 0.99 (s, 3 H, H²⁹), 0.98 (s, 3 H, H²⁵), 0.90 (s, 3 H, H³⁰); ¹³C-NMR (150 MHz, CDCl₃): δ 179.0 (C²⁸), 167.1 (C³), 91.8 (C¹³), 56.4 (C¹²), 55.4 (C⁵), 52.5 (C¹⁸), 45.7 (C¹⁷), 45.3 (C⁹), 43.6 (C¹⁴), 42.5 (C⁸), 40.4 (C⁴), 40.1 (C¹⁹), 38.4 (C¹), 36.7 (C¹⁰), 34.3 (C⁷), 34.0 (C²¹), 33.4 (C²⁹), 32.0 (C²⁰), 30.8 (C¹¹), 29.3 (C¹⁵), 27.6 (C²²), 27.6 (C²³), 23.7 (C³⁰), 22.9 (C²⁴), 21.4 (C¹⁶), 21.1 (C²⁷), 19.0 (C²⁶), 18.6 (C⁶),

16.9 (C²), 16.9 (C²⁵); $[\alpha]_{\mathbf{D}}^{\mathbf{20}}$ +35.5 (c 1.0, CDCl₃); **IR (neat)** 3280, 2956, 2932, 2868, 1775, 1465, **HRMS (ESI-TOF)** m/z: $[M + Na]^+$ Calcd for $C_{30}H_{46}BrNNaO_3^+$ 570.2553; Found 570.2550;

12α-Chloro-3-(methoxyimino)-olean-28,13β-olide (29a)



A round bottom flask, equipped with magnetic stirring bar, was charged with a solution of **27a** (2 mmol, 978 mg, 1 equiv) in pyridine (20 ml). After addition of methoxyamine hydrochloride (4 mmol, 334 mg, 2 equiv), the flask was immersed in a preheated oilbath (80 °C), and the reaction was left stirring at 80 °C for 1.5 h. After cooling to room temperature, the mixture was diluted with DCM (200 ml). The organics were

washed with HCl solution (1 m in H₂O) (3 × 125 ml) and dried over MgSO₄. Removal of the solvents under reduced pressure, followed by drying *in vacuo* gave the target compound as off-white foam (quantitative yield).

¹H-NMR (700 MHz, CDCl₃): δ 4.17 (dd, $\mathcal{J} = 3.9, 2.3$ Hz, 1 H, H¹²), 3.82 (s, 3 H, H³¹), 2.88 (ddd, $\mathcal{J} = 15.6, 6.1, 4.1$ Hz, 1 H, H^{2a}), 2.31–2.24 (m, 2 H, H^{2b,11a}), 2.19–2.13 (m, 2 H, H^{16a,19a}), 2.06–1.98 (m, 2 H, H^{18,19b}), 1.95 (td, $\mathcal{J} = 13.8, 6.1$ Hz, 1 H, H^{15b}), 1.75 (m, 3 H, H^{1a,9,11b}), 1.64 (dd, $\mathcal{J} = 9.3, 3.6$ Hz, 2 H, H^{22ab}), 1.61–1.52 (m, 2 H, H^{6a,7a}), 1.52–1.44 (m, 1 H, H^{6b}), 1.40–1.33 (m, 4 H, H^{21a,27}), 1.34–1.24 (m, 3 H, H^{7b,16b,21b}), 1.23 (s, 5 H, H^{1b,15b,26}), 1.16 (s, 3 H, H²³), 1.14 (dd, $\mathcal{J} = 11.9, 2.2$ Hz, 1 H, H⁵), 1.05 (s, 3 H, H²⁴), 0.99 (s, 3 H, H²⁹), 0.96 (s, 3 H, H²⁵), 0.90 (s, 3 H, H³⁰); ¹³C-NMR (175 MHz, CDCl₃): δ 179.2 (C²⁸), 165.7 (C³), 91.8 (C¹³), 65.1 (C¹²), 61.2 (C³¹), 55.5 (C⁵), 52.1 (C¹⁸), 45.5 (C¹⁷), 44.5 (C⁹), 43.2 (C¹⁴), 42.5 (C⁸), 40.1 (C⁴), 39.9 (C¹⁹), 38.7 (C¹), 36.6 (C¹⁰), 34.2 (C⁷), 34.1 (C²¹), 33.4 (C²⁹), 32.0 (C²⁰), 29.7 (C¹¹), 29.1 (C¹⁵), 27.7 (C²³), 27.6 (C²²), 23.8 (C³⁰), 23.1 (C²⁴), 21.4 (C¹⁶), 20.2 (C²⁷), 18.8 (C²⁶), 18.6 (C⁶), 17.7 (C²), 16.7 (C²⁵); [α]²⁰ +39.0 (c 1.0, CDCl₃); HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd for C₃₁H₄₈ClNNaO₃⁺ 540.3215; Found 540.3212;

23-Acetoxy-3-(acetoxyimino)-12α-chloro-olean-28,13β-olide (7a)

A screw cap vial, equipped with magnetic stirring bar, was charged with a suspension of **6a** (100 μ mol, 50.4 mg, 1 equiv) in a mixture of Ac₂O (2.65 mmol, 250 μ l, 26.5 equiv) and AcOH (250 μ l). The mixture was left stirring at 20 °C for 5 h. Pd(OAc)₂ (12.5 μ mol, 2.8 mg, 0.125 equiv) and PhI(OAc)₂ (150 μ mol, 48.3 mg, 1.5 equiv) were added subsequently and the reaction was left stirring at 20 °C for 48 h. Solvents were removed un-

der reduced pressure at 50 °C. Purification by column chromatography (silica gel, heptane/EtOAc = 4:1) gave the target compound as colourless solid (34.4 μmol, 20.8 mg, 34 %; dr 80:20). ¹H-NMR (600 MHz, CDCl₃, major isomer): δ 4.22 (d, \mathcal{J} = 11.0 Hz, 1 H, H^{23a}), 4.21–4.16 (m, 1 H, H¹²), 4.10 (d, \mathcal{J} = 11.0 Hz, 1 H, H^{23b}), 2.74–2.63 (m, 1 H, H^{2a}), 2.34–2.25 (m, 2 H, H^{2b,11a}), 2.21–2.12 (m, 5 H, H^{16a,19a,32}), 2.07 (s, 3 H, H³⁴), 2.05–2.00 (m, 2 H, H^{18,19b}), 1.94 (td, \mathcal{J} = 13.8, 6.1 Hz, 1 H, H^{15a}), 1.84–1.77 (m, 2 H, H^{1a,9}), 1.76–1.70 (m, 1 H, H^{11b}), 1.68–1.62 (m, 2 H, H^{22ab}), 1.57–1.48 (m, 3 H, H^{5,6a,7a}), 1.47–1.41 (m, 1 H, H^{6b}), 1.39 (s, 3 H, H²⁷), 1.36–1.26 (m, 5 H, H^{1b,7b,16b,21ab}), 1.26–1.21 (m, 4 H, H^{15b,26}), 1.19 (s, 3 H, H²⁴), 0.99 (s, 3 H, H²⁹), 0.94 (s, 3 H, H²⁵), 0.91 (s, 3 H, H³⁰); ¹³C-NMR (150 MHz, CDCl₃, major isomer): δ 179.0 (C²⁸), 171.1 (C³³), 170.4 (C³¹), 169.7 (C³), 91.6 (C¹³), 68.4 (C²³), 65.0 (C¹²), 52.1 (C¹⁸), 48.3 (C⁵), 45.4 (C¹⁷), 44.1 (C⁴), 44.1 (C⁹), 43.2 (C¹⁴), 42.2 (C⁸), 39.9 (C¹⁹), 37.4 (C¹), 36.2 (C¹⁰), 34.0 (C²¹), 33.7 (C⁷), 33.4 (C²⁹), 32.0 (C²⁰), 29.9 (C¹¹), 29.0 (C¹⁵), 27.6 (C²²), 23.7 (C³⁰), 21.4 (C¹⁶), 21.2 (C³⁴), 20.4 (C²), 20.2 (C³²), 20.1 (C²⁷), 19.0 (C⁶), 18.9 (C²⁴), 18.6 (C²⁶), 17.1 (C²⁵), IR (neat) 2941, 2869, 1771, 1743, 1466, HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd for C₃₄H₅₀ClNNaO₆⁺ 626.3219; Found 626.3208;


23-Acetoxy-3-(acetoxyimino)-12α-bromo-olean-28,13β-olide (7b)

A round bottom flask, equipped with magnetic stirring bar, was charged with a suspension of 6b (19.7 mmol, 10.805 g, 1 equiv) in a mixture of Ac_2O (512 mmol, 48.4 ml, 26 equiv) and AcOH (49.25 ml). The flask was immersed into a preheated oilbath (40 °C), and the mixture was left stirring at 40 °C for 2 h. $Pd(OAc)_2$ (2.95 mmol, 663.0 mg, 0.15 equiv) and $PhI(OAc)_2$ (31.5 mmol, 10.150 g, 1.6 equiv) were added subsequently and the reaction was left stir-

ring at 40 °C for 16 h. After cooling to room temperature, MeOH (49.25 ml) was added and the resulting mixture was left stirring at room temperature for 30 min. Solvents were removed under reduced pressure at 50 °C. Purification by column chromatography (silica gel, heptane/EtOAc = 4:1) gave the target compound as colourless solid (9.4 mmol, 6.100 g, 48 %; dr 75:25).

¹H-NMR (600 MHz, CDCl₃, major isomer): δ 4.31 (dd, $\mathcal{J} = 3.9, 2.3$ Hz, 1 H, H¹²), 4.22 (d, $\mathcal{J} = 11.0$ Hz, 1 H, H^{23a}), 4.10 (d, $\mathcal{J} = 11.0$ Hz, 1 H, H^{23b}), 2.74–2.63 (m, 1 H, H^{2a}), 2.46–2.35 (m, 1 H, H^{11a}), 2.34–2.26 (m, 2 H, H^{2b,19a}), 2.20–2.13 (m, 4 H, H^{16a,32}), 2.08 (s, 3 H, H³⁴), 2.01–1.98 (m, 2 H, H^{18,19b}), 1.95 (td, $\mathcal{J} = 13.5, 5.6$ Hz, 1 H, H^{15a}), 1.87–1.72 (m, 3 H, H^{1a,9,11a}), 1.67–1.62 (m, 2 H, H^{22ab}), 1.56–1.49 (m, 3 H, H^{5,6a,7a}), 1.46–1.42 (m, 4 H, H^{6b,27}), 1.40–1.32 (m, 3 H, H^{1b,21ab}), 1.31–1.20 (m, 6 H, H^{7b,15b,16b,26}), 1.19 (s, 3 H, H²⁴), 1.00 (s, 3 H, H²⁹), 0.94 (s, 3 H, H²⁵), 0.90 (s, 3 H, H³⁰); ¹³C-NMR (150 MHz, CDCl₃, major isomer): δ 178.9 (C²⁸), 171.1 (C³³), 170.4 (C³¹), 169.7 (C³), 91.6 (C¹³), 68.4 (C²³), 56.3 (C¹²), 52.5 (C¹⁸), 48.3 (C⁵), 45.6 (C⁹), 44.9 (C¹⁷), 44.1 (C⁴), 43.6 (C¹⁴), 42.3 (C⁸), 40.1 (C¹⁹), 37.3 (C¹), 36.2 (C¹⁰), 34.0 (C²¹), 33.8 (C⁷), 33.4 (C²⁹), 32.0 (C²⁰), 31.0 (C¹¹), 29.2 (C¹⁵), 27.6 (C²²), 23.7 (C³⁰), 21.4 (C¹⁶), 21.2 (C²⁷), 21.0 (C³⁴), 20.3 (C²), 20.1 (C³²), 19.0 (C⁶), 18.9 (C²⁶), 18.8 (C²⁴), 17.3 (C²⁵), IR (neat) 2928, 2863, 1770, 1743, 1465, HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd for C₃₄H₅₀BrNNaO₆ + 670.2714; Found 670.2712;

12α-Bromo-23-hydroxy-3-oxo-olean-28,13β-olide (8b)




A round bottom flask, equipped with magnetic stirring bar, was charged with a solution of **7b** (9.29 mmol, 6.026 g, 1 equiv) and potassium carbonate (9.29 mmol, 1.284 g, 1 equiv) in MeOH (93 ml). The flask was immersed into a preheated oilbath (60 °C) and the reaction was left stirring at 60 °C for 1 h. After addition of THF (93 ml) and a solution of copper sulfate pentahydrate (46.4 mmol, 11.597 g, 5 equiv) in $\rm H_2O$ (93 ml), the resulting suspension was left stirring at 60 °C for 16 h. After cooling to room temperature, the

mixture was extracted with EtOAc (1 × 465 ml and 2 × 232 ml). The combined organic phases were dried over MgSO₄ and concentrated under reduced pressure. Purification by column chromatography (silica gel, heptane/EtOAc = 1:2) gave the target compound as colourless solid (3.83 mmol, 2.105 g, 55 %; dr > 20:1).

¹H-NMR (700 MHz, CDCl₃): δ 4.31 (dd, $\mathcal{J} = 3.9, 2.3$ Hz, 1 H, H¹²), 3.69 (dd, $\mathcal{J} = 11.2, 6.4$ Hz, 1 H, H^{23a}), 3.43 (dd, $\mathcal{J} = 11.3, 6.9$ Hz, 1 H, H^{23b}), 2.64 (ddd, $\mathcal{J} = 16.4, 12.4, 7.2$ Hz, 1 H, H^{2a}), 2.45 (ddd, $\mathcal{J} = 14.9, 12.3, 3.9$ Hz, 1 H, H^{11a}), 2.37 (ddd, $\mathcal{J} = 16.4, 6.1, 2.9$ Hz, 1 H, H^{2b}), 2.33 (dd, $\mathcal{J} = 10.1, 1.9$ Hz, 1 H, H^{19a}), 2.23 (t, 1 H, H^{23-OH}), 2.17 (td, $\mathcal{J} = 13.4, 5.8$ Hz, 1 H, H^{16a}), 2.05–1.94 (m, 4 H, H^{1a,15a,18,19b}), 1.92 (dd, 1 H, H⁹), 1.88 (dt, 1 H, H^{11b}), 1.77 (dd, $\mathcal{J} = 12.1, 2.4$ Hz, 1 H, H⁵), 1.67–1.63 (m, 3 H, H^{7a,22ab}), 1.56 (s, 2 H, H^{1b,6a}), 1.46 (s, 3 H, H²⁷), 1.42 (dq, $\mathcal{J} = 13.3, 3.2$ Hz, 1 H, H^{6b}), 1.39–1.32 (m, 2 H, H^{21ab}), 1.32–1.21 (m, 6 H, H^{7b,15b,16b,26}), 1.09 (s, 3 H, H²⁵), 1.01 (s, 3 H, H²⁴), 1.00 (s, 3 H, H²⁹), 0.91 (s, 3 H, H³⁰); ¹³C-NMR (175 MHz, CDCl₃): δ 218.5 (C³), 178.9 (C²⁸), 91.7 (C¹³), 67.0 (C²³), 56.2 (C¹²), 52.6 (C⁴), 52.5 (C¹⁸), 48.8 (C⁵), 45.7 (C¹⁷), 45.0 (C⁹), 43.7 (C¹⁴), 42.5 (C⁸), 40.1 (C¹⁹), 38.8 (C¹), 36.3 (C¹⁰), 35.3 (C²), 34.1 (C⁷), 34.0 (C²¹), 33.4 (C²⁹), 32.0 (C²), 30.9 (C¹¹), 29.3 (C¹⁵), 27.6 (C²²), 23.7 (C³⁰), 21.4 (C¹⁶), 21.2 (C²⁷), 19.1 (C²⁶), 18.7 (C⁶), 16.8 (C²⁵), 16.8 (C²⁴); [α]²⁰ +53.4 (c 1.0, CDCl₃); IR (neat) 3486, 2937, 2869, 1772, 1698, 1461, HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd for C₃₀H₄₅BrNaO₄ + 571.2393; Found 571.2394;

Hederagonic acid (23-Hydr-3-oxo-olean-12-en-28-oic acid) (1)



A round bottom flask, equipped with magnetic stirring bar, was charged with a solution of **8b** (36.4 μ mol, 20.0 mg, 1 equiv) and zinc dust (1092 μ mol, 71.4 mg, 30 equiv) in AcOH (360 μ l). The flask was immersed into a preheated oilbath (40 °C) and the reaction was left stirring at 40 °C for 2 h. After cooling to room temperature, the mixture was diluted with EtOAc (730 μ l), filtered over a silica pad and was the residue was washed with EtOAc (2 × 360 μ l).

The solution was concentrated under reduced pressure. Purification by column chromatography (silica gel, heptane/EtOAc/AcOH = 55:40:5) gave the target compound as colourless solid ($34.6 \,\mu\text{mol}$, $16.3 \,\text{mg}$, $95 \,\%$). $20 \,\%$ overall yield starting from **5**. The spectroscopic data is in accordance with the literature. [18,64]

¹H-NMR (600 MHz, CDCl₃): δ 5.31 (t, $\mathcal{J} = 3.7\,\text{Hz}$, 1 H, H¹²), 3.65 (d, $\mathcal{J} = 11.3\,\text{Hz}$, 1 H, H^{23a}), 3.42 (d, $\mathcal{J} = 11.4\,\text{Hz}$, 1 H, H^{23b}), 2.83 (dd, $\mathcal{J} = 13.9, 4.7\,\text{Hz}$, 1 H, H¹⁸), 2.63 (ddd, $\mathcal{J} = 16.1, 13.3, 6.8\,\text{Hz}$, 1 H, H^{2a}), 2.27 (ddd, $\mathcal{J} = 16.2, 5.3, 2.5\,\text{Hz}$, 1 H, H^{2b}), 2.04–1.95 (m, 2 H, H^{11a,16a}), 1.95–1.89 (m, 2 H, H^{1a,11b}), 1.77 (td, $\mathcal{J} = 13.9, 4.5\,\text{Hz}$, 1 H, H^{7a,22ab}), 1.74–1.67 (m, 2 H, H^{9,22a}), 1.66–1.54 (m, 4 H, H^{5,7b,16b,19a}), 1.54–1.46 (m, 2 H, H^{6a,15a}), 1.43–1.32 (m, 4 H, H^{1b,6b,15b,21a}), 1.27–1.20 (m, 1 H, H^{21b}), 1.19–1.13 (m, 7 H, H^{19b,25,27}), 1.13–1.08 (m, 1 H, H^{22b}), 1.01 (s, 3 H, H²⁴), 0.93 (s, 3 H, H³⁰), 0.90 (s, 3 H, H²⁹), 0.83 (s, 3 H, H²⁶); ¹³C-NMR (150 MHz, CDCl₃): δ 219.3 (C³), 182.1 (C²⁸), 143.9 (C¹³), 122.4 (C¹²), 67.0 (C²³), 52.5 (C⁴), 49.3 (C⁵), 46.9 (C⁹), 46.6 (C¹⁷), 45.9 (C¹⁹), 41.9 (C¹⁴), 41.2 (C¹⁸), 39.4 (C⁸), 38.9 (C¹), 36.8 (C¹⁰), 35.3 (C²), 33.9 (C²¹), 33.2 (C²⁹), 32.5 (C⁷), 32.2 (C¹⁵), 30.8 (C²⁰), 27.8 (C²²), 26.0 (C²⁷), 23.7 (C³⁰), 23.6 (C¹¹), 23.1 (C¹⁶), 19.2 (C⁶), 17.3 (C²⁶), 17.0 (C²⁴), 15.3 (C²⁵); [α]_D²⁰ +70.9 (c 1.0, CDCl₃); HRMS (ESI-TOF) m/z: [M + Na]⁺ Calcd for C₃₀H₄₅BrNaO₄⁺ 493.3288; Found 493.3288;



Chapter 4

References and Notes

- [1] B.-X.-Z. Liu, J.-Y. Zhou, Y. Li, X. Zou, J. Wu, J.-F. Gu, J.-R. Yuan, B.-J. Zhao, L. Feng, X.-B. Jia, R.-P. Wang, *BMC Complement. Altern. Med.* **2014**, *14*, 412.
- [2] W. A. Jacobs, J. Biol. Chem. 1925, 63, 631-640.
- [3] S. K. Agarwal, R. P. Rastogi, *Phytochemistry* **1974**, *13*, 666–668.
- [4] N. K. Hart, J. A. Lamberton, A. A. Sioumis, H. Suares, Aust. J. Chem. 1976, 29, 655.
- [5] K. Jatczak, G. Grynkiewicz, *Acta Biochim Pol* **2014**, *61*, 227–243.
- [6] H. Yao, J. Duan, J. Wang, Y. Li, Biochem. Syst. Ecol. 2012, 42, 14–17.
- [7] M. Miyakoshi, K. Shirasuna, Y. Hirai, K. Shingu, S. Isoda, J. Shoji, Y. Ida, T. Shimizu, *J. Nat. Prod.* **1999**, *62*, 445–448.
- [8] M. D. Greca, A. Fiorentino, P. Monaco, L. Previtera, *Phytochemistry* **1993**, *35*, 201–204.
- [9] European and Mediterranean Plant Protection Organization, *Bull. OEPP* **2014**, *44*, 457–471.
- [10] J.-J. Li, J. Yang, F. Lü, Y.-T. Qi, Y.-Q. Liu, Y. Sun, Q. Wang, *Chin. J. Nat. Med.* **2012**, *10*, 279–283.
- [11] C. H. Greenberg, L. M. Smith, D. J. Levey, *Biol. Invasions* **2001**, *3*, 363–372.
- [12] C.-S. Chang, H. Kim, H.-S. Kang, D. K. Lee, Bot. Bull. Acad. Sin. 2003, 44, 337–344.
- [13] Z. Shu, Z. Chen, X.-j. Ding, B.-q. Lu, C.-j. Ji, Q.-m. X. X.-r. Li, S.-l. Yang, *Heterocycles* **2011**, 83, 2365.
- [14] Y. Xu, L. Bai, Y. Liu, Y. Liu, T. Xu, S. Xie, Y. Si, H. Zhou, T. Liu, D. Xu, *Molecules* **2010**, *15*, 1891–1897.
- [15] H. Duan, Y. Takaishi, H. Momota, Y. Ohmoto, T. Taki, Y. Jia, D. Li, *Phytochemistry* **2000**, *53*, 805–810.
- [16] (a) R. Vidéki, Floating pennywort, Hydrocotyle ranunculoides (Apiales: Apiaceae) 5396697, Doronicum Kft., **2009**, Bugwood . org (visited on 2017-10-24); (b) A. Gentry, Castor aralia, Kalopanax septemlobus (Apiales: Araliaceae) 5473933, Invasive Plant Control, Inc., **2012**, Bugwood . org (visited on 2017-10-24); (c) J. R. Allison, Oriental bittersweet, Celastrus orbiculatus (Celastrales: Celastraceae) 2105096, Georgia Department of Natural Resources, **2010**, http://Bugwood.org (visited on 2017-10-24).
- [17] C. Basset, Asian flora, 2017, http://www.asianflora.com (visited on 2017-10-24).
- [18] X.-A. Wen, J. Liu, L.-Y. Zhang, P.-Z. Ni, H.-B. Sun, *Chin. J. Nat. Med.* **2010**, *8*, Alternative DOI: 10.3724/SP.J.1009.2010.00441, 441–448.
- [19] Z. Liang, L. Zhang, L. Li, J. Liu, H. Li, L. Zhang, L. Chen, K. Cheng, M. Zheng, X. Wen, P. Zhang, J. Hao, Y. Gong, X. Zhang, X. Zhu, J. Chen, H. Liu, H. Jiang, C. Luo, H. Sun, Eur. J. Med. Chem. 2011, 46, 2011–2021.

- [20] J. Pollier, A. Goossens, *Phytochemistry* **2012**, *77*, 10–15.
- [21] J. Chen, J. Liu, L. Zhang, G. Wu, W. Hua, X. Wu, H. Sun, *Bioorg. Med. Chem. Lett.* **2006**, *16*, 2915–2919.
- [22] J. E. Baldwin, C. Nájera, M. Yus, J. Chem. Soc. Chem. Commun. 1985, 126-127.
- [23] A. G. Constable, W. S. McDonald, L. C. Sawkins, B. L. Shaw, *J. Chem. Soc. Dalton Trans.* **1980**, 1992–2000.
- [24] K. Carr, H. M. Saxton, J. K. Sutherland, J. Chem. Soc. Perkin Trans. 1 1988, 1599–1601.
- [25] T. M. Peakman, H. L. ten Haven, J. Rullkötter, J. A. Curiale, *Tetrahedron* **1991**, *47*, 3779–3786.
- [26] L. Bore, T. Honda, G. W. Gribble, J. Org. Chem. 2000-09, 65, 6278-6282.
- [27] L. V. Desai, K. L. Hull, M. S. Sanford, J. Am. Chem. Soc. 2004-08, 126, 9542-9543.
- [28] B. V. S. Reddy, L. R. Reddy, E. J. Corey, Org. Lett. 2006-07, 8, 3391–3394.
- [29] V. V. Dunina, O. A. Zalevskaya, V. M. Potapov, Russ. Chem. Rev. 1988-03, 57, 250-269.
- [30] A. R. Dick, K. L. Hull, M. S. Sanford, J. Am. Chem. Soc. 2004-03, 126, 2300-2301.
- [31] S. R. Neufeldt, M. S. Sanford, Acc. Chem. Res. 2012-06, 45, 936-946.
- [32] M. Berger, "PhD Thesis, in progress", Maulide Group, University of Vienna, Vienna, Austria, **2017**.
- [33] J. A. Kerr, Chem. Rev. **1966**, 66, 465–500.
- [34] S. R. Neufeldt, M. S. Sanford, Org. Lett. 2010, 12, 532–535.
- [35] K. Lewis, D. Tucker, Aust. J. Chem. 1983, 36, 2297.
- [36] Y. Hayashi, Chem. Sci. 2016, 7, 866-880.
- [37] P. A. Wender, Nat. Prod. Rep. 2014, 31, 433-440.
- [38] E. J. Corey, G. Schmidt, Tetrahedron Lett. 1979, 20, 399–402.
- [39] E. Corey, J. Suggs, Tetrahedron Lett. 1975, 16, 2647–2650.
- [40] B. E. Rivero-Chan, J. G. Marrero, S. Hernández-Ortega, G. J. Mena-Rejón, L. D. Miranda, *Nat. Prod. Res.* **2012**, *26*, 675–679.
- [41] I. Dip, C. Gethers, T. Rice, T. S. Straub, Tetrahedron Lett. 2017, 58, 2720–2722.
- [42] U. Tilstam, H. Weinmann, Org. Process Res. Dev. 2002, 6, 384–393.
- [43] E. C. Juenge, P. L. Spangler, W. P. Duncan, J. Org. Chem. 1966, 31, 3836–3838.
- [44] T. R. Walters, W. W. Zajac, J. M. Woods, J. Org. Chem. 1991, 56, 316–321.
- [45] D. Kaminskyy, B. Bednarczyk-Cwynar, O. Vasylenko, O. Kazakova, B. Zimenkovsky, L. Zaprutko, R. Lesyk, *Med. Chem. Res.* **2011**, *21*, 3568–3580.
- [46] H. E. Elsayed, M. R. Akl, H. Y. Ebrahim, A. A. Sallam, E. G. Haggag, A. M. Kamal, K. A. E. Sayed, *Chem. Biol. Drug Des.* **2014**, *85*, 231–243.
- [47] Y. Y. See, A. T. Herrmann, Y. Aihara, P. S. Baran, J. Am. Chem. Soc. 2015, 137, 13776–13779.
- [48] D. H. R. Barton, P. de Mayo, J. Chem. Soc. (Resumed) 1954, 887.
- [49] S. R. Johns, J. A. Lamberton, T. C. Morton, H. Suares, R. I. Willing, *Aust. J. Chem.* **1983**, *36*, C-4-epi hederagonic acid, 2537.

- [50] R. G. Soengas, H. Rodríguez-Solla, A. Díaz-Pardo, R. Acúrcio, C. Concellón, V. del Amo, A. M. S. Silva, Eur. J. Org. Chem. 2015, 2015, 2524–2530.
- [51] M. B. Sporn, K. T. Liby, M. M. Yore, L. Fu, J. M. Lopchuk, G. W. Gribble, *J. Nat. Prod.* **2011**, 74, 537–545.
- [52] Chemical Abstracts Service: Columbus, OH, Ed., SciFinder, **2017**, https://scifinder.cas.org (visited on 2017-10-23).
- [53] abcr GmbH, abcr Webshop, Article number: AB251630, https://www.abcr.de/shop/de/Oleanolicacid-hydrate-95-327970.html/(visited on 2017-12-13).
- [54] Molport, Molport, Article number: MolPort-035-706-388, https://www.molport.com/shop/moleculelink/WCXZTKJFWJFMJG-A0IBKUJJSA-N/35706388 (visited on 2017-12-13).
- [55] G. R. Fulmer, A. J. M. Miller, N. H. Sherden, H. E. Gottlieb, A. Nudelman, B. M. Stoltz, J. E. Bercaw, K. I. Goldberg, *Organometallics* **2010**, *29*, 2176–2179.
- [56] Bruker AXS Inc., Madison, Wisconsin, USA, SAINT, 2012.
- [57] Bruker AXS Inc., Madison, Wisconsin, USA, SADABS, 2001.
- [58] O. V. Dolomanov, L. J. Bourhis, R. J. Gildea, J. A. K. Howard, H. Puschmann, *J. Appl. Crystallogr.* **2009**, *42*, 339–341.
- [59] G. M. Sheldrick, Acta Crystallogr. C 2015, 71, 3-8.
- [60] G. M. Sheldrick, Acta Crystallogr. A 2008, 64, 112–122.
- [61] A. L. Spek, Acta Crystallogr. D 2009, 65, 148–155.
- [62] C. F. Macrae, P. R. Edgington, P. McCabe, E. Pidcock, G. P. Shields, R. Taylor, M. Towler, J. van de Streek, J. Appl. Crystallogr. 2006, 39, 453–457.
- [63] A. Martinez, A. Perojil, F. Rivas, M. Medina-O'Donnell, A. Parra, *Tetrahedron* **2015**, *71*, Bromolactone of OA (Cmpd 2) full NMR charaterisation., 792–800.
- [64] P. Bhandari, R. P. Rastogi, *Phytochemistry* **1984**, *23*, 2082–2085.



Appendix A

Display Elements

List of Figures

	1.1	Structure of hederagonic acid (1), hederagenin (2) and the oleanae scaffold	1
	1.2	Structure of hederagonic acid saponins	2
	1.3	Selected plants containing hederagonic acid (1)	3
	2.1	Crystal structure of chlorolactone ketone 27a	19
	2.2	Commercial prices of oleanolic acid (5) and hederagonic acid (1)	37
L	ist c	of Schemes	
	1.1	Steps 1–3 of the hederagonic acid (1) semisynthesis reported by Wen <i>et al.</i>	5
	1.2	Steps 4–6 of the hederagonic acid (1) semisynthesis reported by Wen <i>et al.</i>	5
	1.3	Steps 7–9 of the hederagonic acid (1) semisynthesis reported by Wen <i>et al.</i>	6
	1.4	Stoichiometric C–H bond oxidation	7
	1.5	Selected applications of Baldwin's cyclopalladation reaction	9
	1.6	Catalytic C–H bond oxidation reported by Sanford and coworkers	10
	1.7	Catalytic C–H bond oxidation of 2,2-dimethylpentanone oximes 23 and 24	11
	1.8	Catalytic cycle of the C–H bond oxidation, proposed by Sanford and coworkers.	11
	2.1	Concise synthesis of hederagonic acid (1) <i>via</i> catalytic C–H oxidation	13
	2.2	Synthesis of chlorolactone alcohol 26a	14
	2.3	Synthesis of chlorolactone ketone 27a	15
	2.4	Synthesis of chlorolactone oxime 6a	15
	2.5	C–H Acetoxylation of chlorolactone oxime 6a as performed by Berger	16
	2.6	One-pot deacetylation-deoximation of chlorolactone 7a	16
	2.7	Retro-halolactonisation of bromolactone alcohol 26b	17
	2.8	The formation of γ -butyrolactone in the reaction of THF and PCC	18

2.9	One-pot synthesis of chlorolactone ketone 27a	19		
2.10	One-pot synthesis of chlorolactone oxime 6a	20		
2.11	The oxidation of secondary alcohols with TCCA, reported by Dip <i>et al.</i>	21		
2.12	Oxidation of chlorolactone alcohol 26a with TCCA	21		
2.13	Enhanced one-pot synthesis of chlorolactone oxime 6a	23		
2.14	Synthesis of bromolactone oxime 6b reported by Kaminskyy <i>et al.</i>	23		
2.15	Proposed chlorination of succinimide	24		
2.16	Oxidation attempt with NCS	24		
2.17	One-pot synthesis of bromolactone oxime 6b	25		
2.18	Synthesis of 7b	28		
2.19	Synthesis of picolylimine 31a	30		
2.20	One-pot deacetylation-deoximation of bromolactone 7b	32		
2.21	Decarbonylation of $\beta\text{-hydroxy}$ ketone $\textbf{8b}$	32		
2.22	Dually activated retro-aldol formaldehyde elimination	33		
2.23	3 Failed retro-chlorolactonisation of 27a			
2.24	4 Retro-bromolactonisation of 8b			
2.25	The herein reported semisynthesis of hederagonic acid (1)	36		
2.26	β-Hydroxy ketone $8b$ as potential branching point	39		
List o	of Tables			
2.1	Solvent screening for the tandem lactonisation-oxidation with TCCA	22		
2.2	Screening of the C–H acetoxylation of chlorolactone oxime 6a	26		
2.3	Solvent screening for C–H acetoxylation of chlorolactone <i>O</i> -acetyloxime 28a .	27		
2.4	Screening of the C–H acetoxylation of chlorolactone <i>O</i> -acetyloxime 28a	27		
2.5	Screening of the C–H acetoxylation of chlorolactone <i>O</i> -methyloxime 29a	28		
2.6	Screening of the C–H acetoxylation of bromolactone oxime 6b	29		
2.7	Screening of the Schönecker oxidation	31		

Abstract

Hederagonic acid is a natural product belonging to the oleanane family. The triterpenoid consists of five fused six-membered rings and bears several functional groups. Herein, the shortest synthesis of hederagonic acid to date is presented. The synthetic route starts from oleanolic acid, a cheap material providing the carbon skeleton. The initial installation of a multi-purpose halolactone protecting group paves the way towards more complex oleananes. The development of well-designed multi-step one-pot reactions allowed a minimisation of the number of steps. Noteworthy is the use of TCCA, a low-priced chemical widely used as swimming pool disinfectant, as oxidant. Thus, the synthesis not only becomes cheaper, but also presents an alternative to the use of toxic chromium(VI) compounds. Introduction of the C-23 hydroxy group was facilitated by a palladium catalysed C-H acetoxylation with substrate controlled diastereoselectivity. Carefully chosen reaction conditions for this transformation enabled scalability up to 20 mmol. Finally, hederagonic acid is obtained after a deprotection sequence in only four steps.

Zusammenfassung

Hederagonsäure ist ein Naturstoff aus der Familie der Oleanane. Das Triterpenoid besteht aus fünf annelierten, sechsgliedrigen Ringen und trägt diverse funktionelle Gruppen. Hierin wird die bis dato kürzeste Synthese von Hederagonsäure präsentiert. Die Syntheseroute beginnt mit Oleanolsäure, einem günstigen Material, welches das Kohlenstoffgerüst zur Verfügung stellt. Die Installation einer Mehrzweck-Halolacton-Schutzgruppe zu Beginn der Synthese ebnet den Weg hin zu komplexeren Oleananen. Die Entwicklung von hochoptimierten mehrstufigen Eintopfreaktionen erlaubte eine Minimierung der Stufenanzahl. Nennenswert ist die Verwendung von TCCA, eine als Schwimmbad-Desinfektionsmittel weit verbreitete, kostengünstige Chemikalie, als Oxidationsmittel. Dadurch wird die Synthese nicht nur günstiger, sondern präsentiert auch eine Alternative zur Verwendung von toxischen Chrom(VI)-Verbindungen. Die Einführung der C-23-Hydroxygruppe wurde durch eine palladium-katalysierte C-H-Acetoxylierung mit substratkontrollierter Diastereoselektivität ermöglicht. Sorgfältig gewählte Reaktionsbedingungen für diese Transformation erlaubten dabei eine Skalierbarkeit bis hin zu 20 mmol. Letztendlich wird Hederagonsäure nach einer Entschützungssequenz in nur vier Stufen erhalten.